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Solid tumors can have areas of hypoxia. Hypoxia is associated with
changes in tumor cell metabolism, with radiation therapy resistance, with
chemotherapy resistance, and with tumor aggressiveness. Yet most cell culture
research and drug studies are based on cell lines grown in atmospheric oxygen
(normoxia). Our hypothesis was that differences in protein levels, differences in
mitochondrial morphology, and differences in killing of cells by drug
compounds in normoxic and hypoxic conditions would be observed. Normoxic
conditions were achieved by culturing cell lines in humidified incubators
supplemented with 5% CO2. Hypoxic conditions were achieved by culturing cells
in a culture chamber, supplied by InQ Biosystems, which could be adjusted to
1.4% oxygen. The results of examining cells under both conditions showed that
there is a difference in mitochondrial morphology in hypoxic versus normoxic
cells and that the levels of many cellular proteins are different under hypoxia
and normoxia. CA9 and HIF-1α protein levels are both increased in cancer cell
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CHAPTER 1

LITERATURE REVIEW

Cancer is the second leading cause of death in the United States and in
2016 new cancer cases are projected to be 1,685,210 with 595,690 cancer deaths in
the United States alone (Siegel, Miller, and Jemal 2016). There are more than 100
distinct types of cancer with different subtypes of tumor found in each organ
(Hanahan and Weinberg 2000). These subtypes represent biologically distinct
disease entities and may require different therapeutic strategies (Sorlie et al.
2006). Response to treatments can be influenced by the tumor microenvironment
(Vaupel, Kallinowski, and Okunieff 1989; Thews et al. 2004; Thomlinson and
Gray 1955).
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1.1

Tumor microenvironment
A tumor may consist of cancer stem cells, metastatic cancer cells, cancer

associated fibroblasts, endothelial cells, macrophages and more all embedded in
an extracellular matrix (Dayan et al. 2008; Coussens and Werb 2002). Most forms
of human tumors including breast, brain, cervix, head/neck, and soft tissue
sarcomas have areas of hypoxia (less than physiological oxygen) and anoxia
(complete lack of oxygen) (Murdoch, Giannoudis, and Lewis 2004). Solid
tumors, even tumors 1 – 3 mm in diameter, exhibit hypoxic fractions that may
range from 10 – 30% (Yao et al. 2005). Tumors can also have multiple areas of
less than 10 mmHg (Murdoch, Giannoudis, and Lewis 2004). Median pO2 levels
were found to be less than 20 mmHg for most tumors tested (Table 1.1)
compared to normal physiological levels of oxygen (Table 1.2) in tissues (Lee,
Roth, and LaPres 2007; Le et al. 2006; Vaupel, Kallinowski, and Okunieff 1989).
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Table 1.1 Median pO2 levels in some tumors
Cancers:

Median pO2 levels (mmHg)

reference

~ %O2 **

NSCLC (lung)
Adenocarcinomas
Squamous cell carcinoma
Breast Cancers
Cervix cancer:
stage 0
stage I
stage II

0.7 - 46
10 to 12
15
17

Le, 2006
Vaupel, 1989
Vaupel, 1989
Vaupel, 1989

0.09 - 6.1
1.3 - 1.6
2.0
2.2

20
13
5

Vaupel, 1989
Vaupel, 1989
Vaupel, 1989

2.6
1.7
0.7

** O 2% calculated by: (_____ mmHg/760 mmHg) x 100

Table 1.2 Median pO2 levels in some normal tissues
Normal Tissues:

Median pO2 levels (mmHg)

reference

~ %O2 **

Hepatic artery
Spleen
Breast
Brain
Gastric mucosa
Blood draining tissues
Uterine cervix
Sinusoids (liver)
Mammalian embryo
Skeletal muscle
Myocardium

95 - 105
66
65
45 - 65
47
40
36
35 - 45
23 - 38
20 - 30
25

Lee, 2007
Vaupel, 1989
Vaupel, 1989
Lee, 2007
Vaupel, 1989
Lee, 2007
Vaupel, 1989
Lee, 2007
Lee, 2007
Lee, 2007
Vaupel, 1989

12.5 - 13.8
8.7
8.6
5.9 - 8.6
6.2
5.3
4.7
4.6 - 5.9
3.0 - 5.0
2.6 - 3.9
3.3
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Hypoxic areas occur during very early tumor growth stages due to
distance from capillaries or due to microvessel abnormalities (Vaupel,
Kallinowski, and Okunieff 1989). Tumor cells more than 100 to 150μm from the
nearest capillary will experience hypoxia (Nelson and Cox 2005; Thomlinson and
Gray 1955; Brown 1999). Blood vessels, if present in tumors, may be preexisting
vessels that have been incorporated into the tumor tissue. These preexisting
vessels can become elongated, dilated, or they may disintegrate, become
obstructed or compressed (Vaupel, Kallinowski, and Okunieff 1989). Decreased
number of tumor vessels or increased tumor vessel abnormalities can lead to a
reduction of available exchange area for oxygen, nutrients, hormones, growth
factors, and waste products (Vaupel, Kallinowski, and Okunieff 1989). Hypoxia
is associated with changes in cell metabolism, angiogenesis, and increased risk of
metastasis (Favaro et al. 2011).
When an area starts to become hypoxic normal cells will die but the tumor
cells can adapt to low oxygen by uncoupling glycolysis from respiration allowing
glycolysis to be the main source of ATP production (Sonveaux et al. 2008; Larson
2014; Patiar and Harris 2006). Hypoxia stimulates the expression of glycolytic
enzymes (Seagroves et al. 2001). In 1956 Otto Warburg determined that cancer
cells can obtain approximately the same amount of energy from anaerobic
fermentation (measured by the formation of lactic acid in the absence of oxygen)
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as from respiration (measured by oxygen consumption of cells that are saturated
with oxygen) (Warburg 1956). He also determined that cancer cell respiration is
damaged though it does not kill the cell and that the damage is irreversible since
cancer cell respiration never returns to normal (Warburg 1956).
In heterogeneous tumors, glycolytic and oxidative cells mutually regulate
energy metabolites through symbiosis (Sonveaux et al. 2008). Hypoxic cells use
glucose in the glycolytic pathway to produce lactate as an end product
(Sonveaux et al. 2008). Lactate is a fuel for oxidative metabolism of oxygenated
tumor cells (Sonveaux et al. 2008). Cancer cells and normal stromal cells
symbiotically recycle and maximize the use of nutrients (Dang 2012).

1.2

Tumor Treatment
Hypoxia in solid tumors is associated with resistance to radiation therapy

and chemotherapy resistance leading to poor prognosis in these patients (Chi et
al. 2006; Wouters et al. 2007; Vaupel, Thews, and Hoeckel 2001; Thomlinson and
Gray 1955). In 2007, studies showed that under hypoxic conditions cancer cells
have an increased resistance to drugs such as methotrexate, 5-fluorouracil,
doxorubicin, etoposide, gemcitabine, actinomycin D, carboplatin, bleomycin,
paclitaxel, cisplatin, and mitomycin C (Wouters et al. 2007; Koch et al. 2003). In a
2013 study Strese et al. evaluated a variety of cell lines from many sources and
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found that acriflavine, bortezomib, doxorubicin, and etoposide showed a
slightly higher cytotoxic effect in anoxia and hypoxia compared to normoxia;
sorafenib and irinotecan were less effective in anoxia and hypoxia; and docetaxel
and melphalan had a slight decrease in effect in anoxia and hypoxia (Strese et al.
2013). Cisplatin, mitomycin c and tirapazamine were more effective in anoxia
and hypoxia in general (Strese et al. 2013).
Thus, drugs need to be developed and tested under hypoxic/anoxic
conditions in order to best target anoxic and/or hypoxic cancer cells. Prodrugs,
which are drug compounds that are in an inactive form when administered but
convert to an active form during cell metabolism, are in testing to see if they can
reach the hypoxic areas in the tumor and be toxic to the cancer cells but have
minimal toxicity to normal cells (Guise et al. 2014; Foehrenbacher et al.
2013).Examples of prodrugs are nitro compounds, N-oxides, quinones, and metal
compounds (Guise et al. 2014). Hypoxia conditions are needed as well for
prodrug testing.

1.3

Models Used for Tumor Research
Ideally tumor research models should replicate the exact molecular

mechanisms that are responsible for the cancer being studied. Unfortunately the
exact mechanisms responsible for the cancer may not always be known. Some
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common methods in tumor research are 1) xenograph, 2) tissue biopsy, or 3) cell
culture.

1.3.1

Xenographs
The xenograft models are usually mice that have human tumors or cells

from a tumor cell line transplanted either subcutaneous or, in the case of breast
models tumors, implanted in the mammary fat pad of the mouse (Kim, O'Hare,
and Stein 2004). The human tumor cells undergo morphogenesis that reflects
their original phenotype so the mice with xenographs are a relevant model (Kim,
O'Hare, and Stein 2004).

1.3.2

Tissue biopsy
Tissue biopsy involves obtaining surgical samples from patients.

Experiments, including antibody staining, DNA microarrays, and more, can be
done on the tissue if the tumor sample is large enough. Tissue biopsy samples
vary from person to person so it is difficult to reproduce experiments.

1.3.3

Cancer Cell Lines
Cell culture are the in vitro cancer model most widely used by cancer

research labs (Kim, O'Hare, and Stein 2004). Cell lines, available for many cancer
types, are characterized and made commercially available through American
Type Culture Collection (ATCC), Human Tumor Cell Repository, and other
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commercial and non-commercial sources. Some advantages to using cell lines are
that they are convenient, they are available in a variety of cell types, and they can
be frozen in liquid nitrogen for long term storage. Some disadvantages to using
cell cultures are that the cultures lack stromal cells, there are inhibitory
byproducts of cellular metabolism which build up in the culture container, and
cells are grown on flat synthetic substrates like glass or plastic (Dhiman, Ray, and
Panda 2005; Kim 2005).
Cell Culture
Most cell lines are cultured in humidified incubators at atmospheric
oxygen (19% - 21%) supplemented with 5% CO2 as part of the bicarbonate buffer
system when doing cancer research. But in 1984, Balin et al. determined that cells
grew better under reduced oxygen (1.84% - 12.6%) and that elevated oxygen
(26%) could be progressively toxic to cells in culture. In order to study the
growth of cells in low oxygen conditions current cell culture methods have to be
altered in some way to produce the reduced oxygen levels.
To produce a hypoxic environment for cell culture, some investigators
place their cells in cell culture containers then flush them with a mixture of < 2%
O2, 5% CO2, and the remainder nitrogen gas. The container is sealed and
incubated in a cell culture incubator. One disadvantage to this method is that
once these cell containers are opened reoxygenation can take place. Another
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disadvantage is that it takes at least 3 hours of flushing to obtain the desired O2
concentration in the flushed media for hypoxia (Allen, Schneider, and White
2001). Some researchers add chemicals, for example CoCl2, to cell cultures to
simulate hypoxia when the cells are growing in a cell culture incubator
(Krishnamachary et al. 2012; Stoner et al. 2002; Mansfield et al. 2005).
3D cell culture can be done using agar, agarose, matrigel (which is a
reconstituted basement membrane), or a prefabricated scaffold (collagen is most
common). 3D cell culture may have areas of hypoxia present if a spheroid or
aggregate of cells is produced. A disadvantage is that the spheroids, if produced,
have to be removed from the culture for processing which exposes the cells to
oxygen.
A hypoxia workstation can provide conditions of hypoxia to cell cultures.
All work is done inside the workstation which ensures that hypoxia levels are
maintained throughout the experiment. One disadvantage to this is the expense
of the workstation.
Methods of Monitoring Cell Hypoxia
Previous studies have looked for the expression of endogenous hypoxia
markers. One of the major proteins produced during hypoxia is hypoxiainducible factor 1 (HIF-1). Under hypoxia, the oxygen levels decrease, the
pVHL (product of the Von Hippel – Lindau gene) does not bind the HIF-1,
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allowing the HIF-1 protein levels to increase dramatically and the fraction that
is ubiquitinated is decreased (Weinberg 2007; Semenza 2000). HIF-1α becomes
detectable after about 30 minutes of hypoxia and the levels peak at about 4 hours
(Fang, Gillies, and Gatenby 2008). Free HIF-1 travels to the nucleus where it can
dimerize with HIF-1β and then activate the expression of genes by binding to a
HRE (hypoxia response element) located in the enhancer and promoter regions
of many genes (Ke and Costa 2006; Wang et al. 1995; Semenza 2000). HIF-1α is
absent in normal tissue but can be found in detectable amounts in benign tumors
(Ke and Costa 2006). Elevated levels of HIF-1α are detected in primary
malignant tumors with metastatic tumors showing a marked increase in HIF-1α
(Ke and Costa 2006) .
Due to the short half life of HIF-1α, carbonic anhydrase 9 (CA9) and
glucose transporter 1 (GLUT1), both proteins whose expression is increased by
HIF dimer, have been used as endogenous markers to detect hypoxia in tumor
tissue (Rundqvist and Johnson 2013). CA9 is a cell membrane protein which
plays a critical role in many cellular processes such as transport of
CO2/bicarbonate, pH and CO2 homeostasis, electrolyte secretion in a variety of
tissues, and many other physiological or pathological processes (Supuran 2011;
Pastorekov and Z'vada 2004; Rademakers et al. 2011). Increased CA9 and
increased GLUT-1 were found in high grade breast cancer (Rundqvist and
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Johnson 2013). Tumor biopsies have typically shown an increase in HIF-1,
CA9, and GLUT1 which correlates with tumor aggressiveness and poor
prognosis (Jankovic et al. 2006). CA9 and HIF-1α together can be used as
hypoxia markers in tumors to determine the prognosis of many patients with
cancer (Kim et al. 2005; Le et al. 2006; Jankovic et al. 2006). CA9 has been
suggested as a predictive marker for response to chemo and adjuvant treatments
(Rundqvist and Johnson 2013).
Another way to monitor the effect of oxygen levels in cells is to study the
mitochondria. In most normal cells the mitochondria form a reticular network
that radiates from the nucleus (Palmer et al. 2011). According to research done
by Lui et al., depending on cell type, cells that are hypoxic can have
mitochondria that are retained in the perinuclear area, can have shortened
mitochondria due to suppression of fusion, and/or can have donut formation due
to partial dissociation of mitochondria from microtubules and anomalous fusion
activity (Liu and Hajnoczky 2011). The presence or absence of glucose can also
play a role in mitochondrial shape. A medium depleted of glucose but under
hypoxia contains cells with mitochondria that are swollen (donut formation) and
that have severe ATP depletion (Liu and Hajnoczky 2011). Swelling continues
even after 30 minutes of reoxygenation. According to Chiche et al., in their 2010
research, HIF-1α is involved in changes in mitochondrial morphology and
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enlarged mitochondria are functional (based on mitochondrial membrane
potential) and resistant to apoptosis (Chiche et al. 2010).
Another marker that can be used for estrogen receptor positive cells as an
indicator of hypoxia is estrogen receptor alpha (ERα).

Studies show that the

loss of estrogen receptor alpha (ERα) occurs in hypoxia. Under hypoxia the ESR1
gene, which encodes ERα, is repressed at the transcriptional level under HIF-1α
control and the ERα protein is degraded by a proteasome-dependent pathway
(Park et al. 2009; Ryu, Park, and Lee 2011). MCF-7 breast cancer cells, which are
ERα positive under normoxic cell culture conditions, show down-regulation of
ERα after 24 hours under hypoxic conditions (Park et al. 2009). Downregulation
of ERα in some breast cancer cell lines during hypoxia leads to a downregulated
response to tamoxifen, a commonly used drug (Rundqvist and Johnson 2013).

1.4

Objective of This Research
The objective of this research was to determine if hypoxic cell culture

methods could be developed and used to study drug efficacy under conditions
that better matched in vivo conditions in tumors (Figure 1.1). This was
investigated by culturing cell lines under various conditions of normal
atmospheric oxygen (normoxia) and hypoxia. Antibodies to ERα, CA9, and HIF1α were used to quantitate their protein levels. Mitochondrial morphology and
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cellular morphology were observed using confocal microscopy. Drug
compounds were tested for cytotoxicity under normal atmospheric oxygen and
hypoxia. It was hypothesized that there would be a difference in the protein
levels of ERα, CA9, and HIF-1α and that there would be a difference in drug
cytotoxicity between the two conditions. It was necessary to develop a method
for hypoxic cell cultures that was readily available and consistent. This new
hypoxia system, gradient coverslip (gCVSL), needed to provide a cell culture
environment that allows for varying oxygen levels as well as nutrient levels, pH
levels, and waste levels. Having a better cell line model system to represent
hypoxic and anoxic regions in tumors will allow for drug studies to find
compounds that can kill oxygenated tumor cells as well as hypoxic tumor cells.
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Capillary
“Cells about to
leave the tumor”

“Neighboring Cells”
“Normal Cells”

“Hypoxic Cells”

“Anoxic Cells”

Figure 1.1 Drawing representing a tumor: Normal cells are located near the capillaries
and as cells get further away from a blood supply they become more hypoxic and even
anoxic if the distance is too great. Neighboring cells, between hypoxic cells and normal
cells, receive different signals from each cell type and they can help the hypoxic cells
survive.
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CHAPTER 2

CELL CULTURE

2.1

Introduction
The two dimensional culture of cancer cell lines is the current method

used in cancer research laboratories for studying cellular metabolism, genetic
profiling, drug sensitivities, many other cellular activities. These cell lines are
immortal which allows for a continuous supply of a relatively homogenous cell
population for experiments.

2.2

General Materials and Methods for Cell Culture
Aseptic technique was used for all phases of tissue culture. Cell culture

procedures were carried out in a Fisher Hamilton SAFEAIRE Class II biosafety
hood with a 0.22 micron HEPA filter to maintain a sterile environment. All of the

15

media and equipment used were sterilized by sterile filtration, gamma radiation,
autoclaving, dry heat, or other appropriate methods.
Human cell lines used included MCF-7 (estrogen receptor positive breast
cells), CAMA-1 (estrogen receptor positive breast cells), Hs578T (triple negative
breast cells), MDA-MB-468 (triple negative breast cells), as well as mouse 3T3
embryonic fibroblasts. Hs578T (ATCC# HTB126), MDA-MB-468 (ATCC# HTB132), MCF-7 (ATCC# HTB-22), and mouse 3T3 (ATCC# CCL-92) were originally
purchased and characterized by American Type Culture Collection (ATCC) and
have since been maintained in a liquid nitrogen dewar when not in use. CAMA-1
cells were a gift from InQ Biosystems. Feeding media for cell growth was RPMI
1640 (Sigma R6504) supplemented with 10% fetal bovine serum (Premium Fetal
Bovine Serum Atlanta Biologicals S11150), 20 mM sodium bicarbonate (Sigma
S8761), 15 mM HEPES (Sigma H4034), and 100 U/ml penicillin with 0.1 mg/ml
streptomycin (Sigma P4333). Other reagents for cell culture experiments were
Hanks Balanced Salt solution, calcium and magnesium free, 10x, (Sigma H4641);
and Trypsin/EDTA, 10x, (Sigma T4174). For general cell culture methods T-25
tissue culture flasks, Corning (Fisher number 10-126-30), were used. For MTT
cytotoxicity assays 96 well flat bottom plates, Costar/Falcon 353072 (Fisher
number 08-772-2C), were used. Reagents for immunocytochemistry (ICC)
included 4% paraformaldehyde in 0.1 M Phosphate buffer, pH 7.35; Bovine
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Serum Albumin fraction V (BSA, Fisher BP-1605), Phosphate Buffered Saline pH
7.35 (0.137 M NaCl, 0.001 M KH2PO4, 0.002 M KCL, and 0.01 M Na2HPO4 · 7H20
into 1 liter total volume of sterile water and then autoclaved to sterilize), PBS
supplemented with 0.5% Tween 20 (PBST), CA9 Mouse mAb [2D3] (Abcam
ab107257); ERα Rabbit mAb (Epitomics 2614-1); HIF-1α Rabbit mAb (Epitomics
2015-1); CA9 Rabbit pAb (Epitomics S1155); Alexa 488 IgG (H+L) goat antimouse antibody (Molecular Probes A11001); and Alexa 594 IgG (H+L) goat antirabbit antibody (Molecular Probes A11012). To test for live versus dead cells
trypan blue (Sigma T8154) was used. Live cell mitochondria were monitored
with Mitotracker Red CMXRos (Molecular Probes M7512). Thiazolyl Blue
Tetrazolium Bromide (Sigma M2128) was used for the cytotoxicity assays. DMSO
(Sigma D2650), Sanguinarine (Sigma S5890), Doxorubicin (Sigma D1515), and
Tingenone (Dr. William Setzer’s lab) were used to make up the drug compounds
for testing.

2.2.1

Frozen Cells
Cryotubes containing frozen cells were removed from the liquid nitrogen

dewar and gently agitated in the 37°C waterbath (~1-2 minutes) until thawed.
The tube was then taken to the biosafety hood where the cells were aspirated
with a 5 ml pipet and quickly placed in a sterile centrifuge tube. Pre-warmed
feeding media was added drop by drop to the tube containing the cells with
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gentle swirling between drops for at least the first 2 ml media then the remaining
3 ml of media was added. Cells were pelleted gently by centrifugation for 2
minutes. The supernatant was aspirated from the pellet then 10 ml fresh feeding
media was added to the cell pellet. The media with cells was pipetted up and
down several times until a cell suspension was achieved. Half of the cell
suspension was placed into each of two T-25 ml cell culture flasks. The T-25
flasks were placed in a humidified 37°C incubator under atmospheric oxygen
(21%O2) supplemented with 5% CO2. After 24 hours the cells were observed for
proper morphology and adherence to the flask surface (if adherent cell line). If
the majority of the cells had adhered then the media in each flask was aspirated
to remove any non-adherent cells and replaced with fresh feeding media. The
media was replaced as needed (usually every other day) until cells reached
approximately 80% confluency. At this point cells were subcultured.

2.2.2

Subculture
Before subculture (splitting) of confluent cells the 1x Hanks pH 7.35 (50 ml

of 10x Hanks, 15 ml of 1 M HEPES, and 400 ml sterile water), the feeding media,
and the 1x trypsin/EDTA (1 ml of 10x trypsin in 9 ml of 1x Hanks) were prewarmed in a 37°C water bath. Flasks were removed from the incubator and taken
to the hood. Media was removed and the flasks containing cells were rinsed with
1x Hanks to remove serum and then 2 ml of 1x trypsin/EDTA solution was
18

added to the flasks and allowed to sit at room temperature on the cell surface
until the cells dislodge from the bottom of the flask. Once this occurred, 5 ml
media with serum (feeding media) was added to the cells to stop the action of the
trypsin. The media containing cells was removed to a screw top sterile centrifuge
tube and centrifuged for 2 minutes. Under the hood the media was aspirated
without removing the cells. To the cell pellet 1x Hanks was added and the cells
were mixed by up/down with a pipette. In another small tube 0.6 ml of 0.9%
sodium chloride solution and 0.3 ml trypan blue was added then 0.1 ml of well
mixed cells was added. The cell/trypan blue solution was gently mixed then both
sides of a Neubauer hemocytometer were loaded. Live (clear) cells in the four
large squares on the corners of the grid (1 mm square) for both sides of the
hemocytometer were counted then the average number of cells per grid was
determined. The cell count was the average number x 104 cells/grid. This number
was multiplied by 10 since there was a dilution of 10 for 0.1 ml cells in 0.9 ml
trypan solution. Once the cells were counted the appropriate amount of cells
were plated.
Cultures were placed in a humidified 37°C incubator under atmospheric
oxygen (21%O2) supplemented with 5% CO2. Cellular morphology and growth
times were monitored using an Olympus CK2 phase contrast inverted
microscope.
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2.2.3

MTT Cytotoxicity Assay
A 5 mg/ml MTT (3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium

bromide) solution was made by dissolving 0.05 g Thiazolyl Blue Tetrazolium
Bromide in 10 ml PBS. It was sterile filtered, wrapped in foil due to light
sensitivity, and the unused portion was frozen. For MTT assays, the cells were
plated in a 96 well plate (day 0) at a cell density of:
1.0 × 104 cells per 100 µl media/well
and the cells were allowed to grow for 2 days. If the cell density was at the
desired level the media was removed and new media was added along with any
drug compounds to be tested (day 2) and these wells were then incubated for 2
more days. At this point (day 4) the media/drug was removed and fresh growth
media (100 µl) was added along with the MTT solution (20 µl). A SpectraMax
Plus 384 plate reader set at 570 nm wavelength, was used to measure the
absorbance of each well immediately after addition of the MTT (pre-read) to use
as a blank. Then the plate is incubated for 4 hours to allow blue insoluble
formazan crystals to be formed by the live cells. After incubation the remaining
MTT/media solution was carefully removed and DMSO (100 µl) was added to
dissolve the crystals. When the crystals were dissolved, the plate was gently
tapped to mix the solutions in the well, and then another spectrophotometric
reading at 570 nm (post-read) was done. Each sample was done in quadruplicate
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and the average ± standard deviation was calculated. The average post-read
minus the average pre-read gave the final absorbance value of the sample. To
calculate the % kill each sample was compared to the DMSO control (or control
solution the drug was diluted in).
Most of the natural drug products used in the MTT assay started with an
initial concentration of 1% compound dissolved in DMSO. This 1% drug
compound was then diluted as 1 µl compound/100 µl media. This was the first
compound concentration to be screened in normoxia in 96 well plates. Most of
the compounds used in this research were dissolved in DMSO so a DMSO
negative solvent control (1 µl DMSO/ 100 µl media) was used to verify that
DMSO is not cytotoxic itself. Tingenone, a natural product, is 100% cytotoxic to
MCF-7, Hs578T, and 3T3 cells at the concentration used (1 µl tingenone/ 100 µl
media) so it was used as a positive control. Drug compounds concentrations and
controls were adjusted as needed for experiments.
When doing a MTT assay it was important to observe each well and the
plate as a whole throughout the experiment. Things noted at each step of the
procedure : 1) were the cells adhering to the plate, 2) were the cells still
proliferating, 3) were there any precipitants in the well, 4) were there drug
crystals in the well after the drug compound was added, 5) were there MTT
formazan crystals present after the MTT solution was added and incubated, 6)
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had crystals and cells been aspirated from the well at any time, 7) were the
formazan crystal dissolved completely, and 8) did these observations match the
spectrophotometric results.
MTT Assay in Reagents without Cells
For reagent MTT assays, 100 µl each of PBS, water, RPMI1640, DMEM,
FBS, RPMI 1640 with FBS, DMEM with FBS, and PBS with FBS were added to 96
wells plates and incubated for 24 hours. Following incubation the wells were
observed microscopically then MTT (20 µl) was added to each well. Average OD
readings were taken before MTT addition (media only) then after MTT addition
to get a “pre-read” value for each sample using a SpectraMax plate reader set at
570nm wavelength. This pre-read value was taken to use as a blank. Another
spectrophotometric reading (post-read) was done after 24 hour MTT incubation
(24 hours post-read), and after 96 hours MTT incubation (96 hours post-read).
Absorbance values were calculated by taking the 24 hour post MTT read value
and subtracting the pre-read value. Photos were also taken at 96 hours of some
of the crystals present in media after reduction of MTT.

2.2.4

Immunocytochemistry (ICC)
A basic Abcam single stain or double stain ICC procedure for adherent

cells was followed for staining procedures (Abcam). For double staining the cells
on coverslips were quickly rinsed twice with PBS then fixed with 4%
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paraformaldehyde for 8 to 9 minutes. The paraformaldehyde is removed to an
approved waste container then the cells were rinsed twice with ice cold PBS. The
cells were permeabilized with PBS containing 0.5% Tween 20 for 10 minutes then
3 rinses of 5 minutes each were done. The cells were blocked for 30 minutes in
PBST containing 1% BSA. After blocking the first primary mouse antibody in 1%
BSA in PBST is added for 1 hour at room temperature or overnight at 4°C
depending on the concentration of the antibody added and the accessibility of
the antigen. After incubation the first primary antibody solution was removed
and the cells were washed three times in PBS, 5 min each wash. The first
secondary antibody, goat anti-mouse IgG Alexa 488, in 1% BSA in PBST was
added for 1 hour at room temperature and the sample was kept in the dark. The
first secondary antibody solution was removed and the sample was washed
three times with PBS for 5 minutes each while minimizing exposure to light.
Blocking solution, to block unspecific binding of the antibodies, was added to the
cells and allowed to sit for 30 minutes at room temperature in the dark. Blocking
solution was removed and then the second primary rabbit antibody in 1% BSA in
PBST was added to the cells and the sample was again kept in the dark for 1 hour
at room temperature or overnight at 4°C depending on the concentration of the
antibody and the accessibility of the antigen. The second primary antibody
solution was removed and the cells were washed three times in PBS for
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5 minutes each while minimizing exposure to light. The second secondary
antibody, goat anti-rabbit IgG Alexa 594, in 1% BSA in PBST was added to the
sample and incubated for 1 hour at room temperature and again the sample was
kept in the dark. The second secondary antibody solution was removed and the
sample was washed three times with PBS for 5 minutes each in the dark. To
stain the nuclear DNA the cells were incubated with 0.1-1 μg/ml Hoechst or
DAPI (DNA stain) for 1 - 15 minutes in dark. The sample was rinsed with PBS.
The coverslip with cells was mounted upside down on a glass slide containing a
drop of mounting medium. The coverslip was sealed with nail polish to prevent
drying and movement under microscopy. The slides were examined with the
confocal microscope. After microscopy the slides were saved in the dark at 4°C.

2.2.5

Mitotracker Red to Identify Mitochondria in Cells
Mitotracker Red CMXRos experiments were based on the Invitrogen/

Molecular Probes procedure. Stock solution of Mitotracker red (MW 531.52) was
prepared by diluting 50 µg powder with 100 µl of high quality DMSO for a stock
concentration of 1 mM. This stock solution was protected from light and stored
at -20°C. To prepare a working solution 1 µl of 1 mM stock Mitotracker Red was
diluted per 2000 µl of warm 1x Hanks Balanced Salt Solution (1x HBSS) for a
final concentration of 500 nM.
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For cells growing on coverslips in a 6 well plate, the media was removed
from the cells and then the cells were rinsed with pre-warmed 1x HBSS. The 1x
HBSS was removed and replaced with 2000 µl of the pre-warmed 1x HBSS
containing the Mitotracker Red. The cells were incubated for 15 – 45 minutes
under growth conditions appropriate for the cells. After incubation the “stain”
was removed and the cells were rinsed with pre-warmed 1x HBSS two times. For
live cell microscopy, the coverslips are ready to be mounted upside down on a
glass slide containing a drop of mounting media. For fixed cell microscopy the
cells can be fixed and permeabilized (following the ICC procedure) without
washing away the mitochondria stain.

2.2.6

Confocal Microscopy
The Zeiss LSM700 confocal microscope (Figure 2.1) was started by turning

on the power strips, the computer, and the microscope (button on the left side
under the danger sign). The slide was placed on the microscope stage with the
coverslip facing downward toward the objectives. The silver lever (Figure 2.2)
was on 0 for microscope use.
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Figure 2.1 Zeiss LSM700 confocal microscope with the slide positioned on the stage.

(for Koehler alignment if needed)

silver lever is on 75
for computer screen
(for Koehler alignment if needed)

button to change
to DICII or DICIII

slide holder
(on the stage)

Figure 2.2 Close up view of the microscope
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Next the Touchpad (Figure 2.3) was used by 1) on the Home screen touch
“make it visible” to view the sample, 2) touch the Microscope button and under
“Objectives” touch the 10x box, 3) touch the Reflector button and touch POL
(polarizer), 4) turn ON TL Illumination by touching the ON box and 5) turn OFF
RL Illumination by touching the OFF box. Next the microscope was used to
focus on the cells. Once focused on 10x then immersion oil was added to the 63x
objective. On the touchpad under “Objectives” the 63x box was selected. The 63x
objective rotated into a low position. On the pop up screen “done” was touched
and then the objective moved into position and touched the slide. On the
microscope DICIII was selected using buttons to the right of the condenser. The
microscope focus was adjusted with fine focus knob. Once the area was found
using the microscope the silver lever was moved to 75 to switch to the computer
screen.

Figure 2.3 The touchpad with the white and blue screen is in the front center of this
photograph.
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On the computer screen Zen 2009 was selected to start the system. This
turns on the lasers and brings up the Zen 2009 screen. On the left side of the
screen (Figure 2.4) there are options “Ocular”, “Acquisition”, “Processing”, and
“Maintain”. Acquisition was selected then located slightly under that “Smart
Setup” was selected. A Smart Setup window came up with a “Configure your
experiment” box. There the dyes were selected from the list of fluorescence dyes
and the color was selected to go with it. Sequential scanning (one detector and
one laser are switched on at anyone time) was used and the Best Signal option
(minimized cross talk) was chosen for these experiments on the smart setup
screen (Figure 2.5).
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Figure 2.4 Acquisition screen: Red arrow points to Smart set up area, blue arrow points
to tracks, green arrow points to area where gains are adjusted, black circle is area for
“live” and “continuous” buttons to start lasers.
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Figure 2.5 The smart setup screen for the Zen 2009 software
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After the smart set up is complete the “live” button (circled in Figure 2-4)
was pressed to run the confocal while focusing on the cells on the computer
screen. The pinhole size was set to 1 AU (Airy Unit). The pinhole adjustment
changes the optical slices thickness. After the cells were found to be in focus then
each laser was used to image individually. The 405 laser was used first to look at
the blue for the nucleus to insure that the confocal was looking about midway
through the cell. Next the gray levels were checked for the nucleus. This was
done by selecting the continuous button to scan in a continuous mode and by
clicking inside the color field in the button under the channel button. The
scanned image appeared in a false-color (red and blue pixels appeared). If the
image was too bright, it appeared red which equals saturation (Figure 2.6 A). The
master gain was reduced until there were only few (or no) red pixels. If the
image was not bright enough, it appeared blue which equals zero. The Digital
offset was adjusted until only few blue pixels were present (Figure 2.6 B). Once
the nucleus checked out then it was switched to the green laser 488 and the gray
levels were checked. This was then repeated with the red laser 594. After all the
lasers were checked out individually they were run together using the sequential
scanning mode to verify that the gray levels were still acceptable.
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A

B

Figure 2.6 Gray levels for image optimization: A) saturated image, B) not saturated
image

Before live samples were run the T-PMT box and DICIII were verified to
be checked. Once all the set up was completed the confocal was run in live mode
for several full scans. The image of the sample appeared on the computer screen.
By clicking on the split button multiple tracts were viewed at the same time
(Figure 2.7). After enough scans were completed the run was stopped and the
snap (average) button was pressed. Photographs were saved as lsm5 files.
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Figure 2.7 Example scan with a split screen view of the sample: upper left shows blue
color indicating nucleus stained with Hoechst 33258, upper middle has T-PMT turned
off, upper right shows green color indicating an antibody tagged with Alexa 488, bottom
left shows red color indicating an antibody tagged with Alexa 594, and bottom middle
shows the combination of them all.
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Wavelengths of 494 nm were used to excite the samples with 517 nm
emissions to visualize the light green visible color for Alexa 488. Wavelengths of
590 nm were used to excite the samples with 617 nm emissions to visualize the
red visible color for Alexa 594. Wavelengths of 345 nm were used to excite the
samples with 455 nm emissions to visualize the blue visible color for DAPI or
Hoechst 33258 which stains the nucleus (DNA) in fixed cells. Wavelengths of
579 nm were used to excite the sample with 599 nm emission to visualize the red
visible color for mitotracker red. Other settings included: frame size of 512x512,
8 bit depth, and averaging of 2, or for higher resolution a frame size of 1024x1024
with 12 bit depth and averaging of 2 was done.
Confocal Notes
To determine if a protein marker was in the nucleus or located
above/below the nucleus several Z stack experiments were done. Z stacks slice
through the cell from top to bottom to provide a unique way to view the layers of
the sample (Figure 2.8). This is especially true for thick samples like
Caenorhabditis elegans (C. elegans) but less advantageous for thin samples like
cells. The easiest and fastest way to determine if a protein was nuclear,
cytoplasmic, or both was to focus all the way through the sample then back the
other way again to see where the protein was located at. Once this was done then
the sample focus was such that the nucleus was visible and in focus indicating
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the mid region of the cell. This was the standard way used to examine all cell
samples.
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Figure 2.8 A, B, and C shows focus used for the same photograph with different
markers. A) 2 protein markers (red and green) with a blue nucleus, B) 1 protein marker
(red) with a blue nucleus, C) 2 protein markers (red and green). D, E, F shows an
example of slices in a Z stack experiment using ERα only (red). D) a top slice, E) a
middle slice where the normal focus was, and F) a bottom slice. For all photographs A-F,
green is CA9 which is cytoplasmic in MCF-7, red is ERα, and blue is the nucleus. (630x
magnification)
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2.2.7

Phase Contrast Inverted Microscopes
Cells in tissue culture flasks, petri dishes, 96 well plates and 6 well plates

were all observed utilizing an Olympus phase contrast inverted microscope and
a Zeiss phase contrast inverted microscope. Both microscopes had 10x oculars.
The objectives on the Olympus included 4x, 10x, and 20x. The Zeiss objectives
were 10x and 20x.

2.2.8

Photograph Processing for Publishing
The Microsoft Office 10 sharpen and soften feature was used to sharpen

the cell images for publishing and printing (Figure 2.9). The confocal images
were taken and saved as .lsm5 which can be converted to .tiff files if high
resolution was used during photography. ICC .tiff photographs ‘sharpen and
soften’ as well as brightness was increased to aid in photograph visibility for
publishing and printing (Figure 2.10).
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A

B

Figure 2.9 A) jpeg from Olympus camera B) Microsoft Office 10 sharpen and soften
feature. Both photographs have been cropped.

A

B

C

Figure 2.10 Example photographs without and with sharpen, soften, and/or brightness.
A) tiff, B) tiff+ sharpen and soften, C) tiff + sharpen and soften + brightness.
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2.3

Cell Culture Results

2.3.1

Cell Proliferation
MCF-7, Hs578T, MDA-MB-468, CAMA-1 and mouse 3T3 cells were grown

in normoxia with RMPI 1640 supplemented with 10% fetal bovine serum. The
cell lines had to be divided into new flasks (split) usually once a week to
maintain the cell line. Results showed that these cell lines proliferate (Figure 2.11)
under these conditions.
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B

E

D

Figure 2.11 A) Hs578T and B) MCF-7 cells grown in T-25 flasks for 2 days in an
incubator with atmospheric oxygen and 5% CO2 , C) MDA-MB-468 cells in normoxia for
3 days, and D) mouse 3T3 fibroblasts in normoxia for 5 days, E) CAMA-1 cells in
normoxia for 21 days (200x magnification).
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Super-confluent MCF-7 cells were obtained when cells were allowed to
grow in a T-25 flask for 1 month (Figure 2.12). Cells were fed every 1 to 2 days to
provide fresh nutrients to and remove metabolic wastes from the cells. At three
weeks growth there were mounds of cells on the cell monolayer but by the forth
week cells were detaching from the surface and “holes” were present in multiple
locations throughout the flask. While MCF-7 cells mound up when superconfluent, the 578T cells continue to layer forming multiple layers with no
mounds (photo not shown).

superconfluent
MCF-7

Figure 2.12 Super-confluent MCF-7 cells were grown in a flask without being split.
Cells were allowed to grow for 1 month before this photo was taken (100x
magnification).

2.3.2

pH
As Hs578T cells proliferate they turn the phenol red in the media to

yellow/orange indicating a decrease in pH (Figure 2.13). MCF-7 and CAMA-1
cells do not reach yellow but they do turn the red into an orange/red color
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indicating slight decrease in pH. To test for the affects of pH on cells, cells were
plated at various pHs and the cells were allowed to grow. Both MCF-7 (Figure
2.14) and Hs578T cell (not shown) lines had normal cell morphology and
proliferated in feeding media from pH 8.69 to pH 6.66. Between pH 6.66 to pH
5.98 some cells proliferated and still looked good but some cells started to round.
Cells at pH 3.91 and pH 2.4 had all round cells and no visible proliferation. Tests
in pH above 8.69 were not conducted. The experiment was repeated with MCF-7
cells to find the lowest pH for these cells to survive. The pHs tested were 7.3,
6.61, 6.15, 5.94, 5.73, 5.41, 5.03, and 4.52. After 24 hours the cells in pH 7.3 to 5.73
had growth and attachment. Cells in pH 5.41 had approximately 50% attachment
and 50% not attached. For pH 5.03 and 4.52 cells were round, refractive, and
unattached (dead). These results showed that MCF-7 and Hs578T cells proliferate
in a range of pH conditions from at least 8.69 to 5.41. The effect of pH on cell
growth became an important factor in future hypoxia experiments.
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T-25 flasks

Figure 2.13 Cell culture flasks (T-25) containing MCF-7 cells (left) and Hs578T cells
(right) after 2 days growth in feeding media (RPMI 1640 supplemented with FBS) which
contains the pH indicator phenol red.
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Figure 2.14 MCF-7 cells cultured for 2 days in feeding media at: A) pH 8.69, B) pH 7.3,
C) pH 7.14, D) pH 6.66, E) pH 5.98, F) pH 3.91, G) pH 2.40 (all photos at 200x
magnification).
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2.3.3

Antibody Results

ERα in MCF-7
MCF-7 cells are estrogen receptor positive so they should have a large
amount of ERα present. ERα presence was determined by ICC as described in
section 2.2.4. The normoxic results indicate that a heavy amount of ERα was
located within the nucleus of the MCF-7 cells (Figure 2.15). Five different
photographs were used to calculate the quantity of cells that stained for ERα. In
normoxia 91% of the cells contained ERα in their nucleus.
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Figure 2.15 ICC photographs for ERα (red), nucleus (blue) in MCF-7cells grown on
coverslips: A) atmospheric oxygen (normoxia); B) same as photograph A but with the
nucleus removed from the photograph; C) graph showing the average number (mean ±
SD) per field of view for MCF-7 cells (purple) photographed that stained for ERα (red);
and D) graph showing % of MCF-7 cells with ERα in normoxia. (630x magnification)
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CA9 and HIF-1α in MCF-7
Presence or absence of CA9 andHIF-1α was determined by ICC as
described in section 2.2.4. In normoxia, MCF-7 cells had CA9 present in the
cytoplasm and HIF-1α present in the nucleus (Figure 2.16). Four different
photographs were used to calculate the quantity of cells that stained for CA9 and
HIF-1α. In normoxia 93% of the cells contained HIF-1α and 44% of the cells
contained CA9.
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Figure 2.16 ICC photographs for MCF-7 cells grown on coverslips in normoxia
(atmospheric oxygen): A) CA9 (green) only; B) HIF-1α (red), nucleus (blue), and CA9
(green); C) HIF-1α (red) only (630x magnification). D) graph showing the average
number (mean ± SD) per field of view for MCF-7 cells (purple) photographed that
stained for CA9 (green) and HIF-1α (red); and F) graph showing % of MCF-7 cells with
CA9 (green) and HIF-1α (red) in normoxia.
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CA9 and HIF-1α in Hs578T
Presence or absence of CA9 andHIF-1α was determined by ICC as
described in section 2.2.4. In normoxia, Hs578T cells had CA9 and HIF-1α
present in both the cytoplasm and nucleus (Figure 2.17). Four different
photographs were used to calculate the quantity of cells that stained for CA9 and
HIF-1α. In normoxia 89% of the cells contained CA9 and 56% of the cells
contained HIF-1α.
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Figure 2.17 ICC photographs for Hs578T cells grown on coverslips in normoxia
(atmospheric oxygen): A) CA9 (green) only; B) HIF-1α (red), nucleus (blue), and CA9
(green); C) HIF-1α (red) only (630x magnification) D) graph showing the average
number (mean ± SD) per field of view for Hs578T cells (purple) photographed that
stained for CA9 (green) and HIF-1α (red); and E) graph showing % of Hs578T cells with
CA9 (green) and HIF-1α (red) in normoxia.
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CA9 and HIF-1α in MDA-MB-468
Presence or absence of CA9 andHIF-1α was determined as described in
section 2.2.4. In normoxia MDA-MB-468 cells have CA9 present in the nucleus
and HIF-1α present in the nucleus (Figure 2.18). Two photographs were used to
calculate the quantity of cells that stained for CA9 and HIF-1α. In normoxia 100%
of the cells contained CA9 and 100% of the cells contained HIF-1α.
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Figure 2.18 ICC photographs for MDA-MB-468 cells grown on coverslips in normoxia
(atmospheric oxygen): A) CA9 (green) only; B) HIF-1α (red), nucleus (blue), and CA9
(green); C) HIF-1α (red) only (630x magnification). D) graph showing the average
number (mean ± SD) per field of view for of MDA-MB-468 cells (purple) photographed
that stained for CA9 (green) and HIF-1α (red); and E) graph showing % of MDA-MB-468
cells with CA9 (green) and HIF-1α (red) in normoxia.
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CA9 and HIF-1α Cell Line Comparison in Normoxia
In normoxia there is a difference in the CA9% and HIF-1α% found in the breast
cancer cell lines as shown in Figure 2.19.

Comparing Normoxia Percentages
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% of cells with CA9

40

% of cells with HIF-1α

30
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10
0
Normoxia
MCF-7

Normoxia
Hs578T

Normoxia
MDA-MB-468

Figure 2.19 Comparison of CA9% and HIF-1α% between 3 breast cancer cell lines: CA9
(green) and HIF-1α (red) in normoxia.

Controls for Immunocytochemistry
Controls that were done for these ICC experiments included Hoechst
33258 to stain the nucleus and to ensure that there was no mycoplasma present.
All the nuclei in the cells stained with the Hoechst 33258 as expected. No
mycoplasma was detected in any of the cell lines used. Alexa 488 and Alexa 594
(secondary antibodies) were added to cells without the primary antibody to
ensure that nothing in the cells would bind to the secondary antibody and that
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there would be no unexpected fluorescence (Figure 2.20). Along with these
controls the experiments themselves provide some “control”. ERα was not
present in normoxic or hypoxic Hs578T cells as expected. ERα was not present in
hypoxic MCF-7 cells but it was present in normoxic MCF-7 indicating that there
was no autofluorescence in the hypoxia sample either.
Multiple experiments were set up for double staining with CA9 (antimouse) and HIF (anti-rabbit), CA9 (anti-mouse) and ERα (anti-rabbit), as well as
anti-rabbit CA9 or anti-mouse CA9 alone.

A

B

Figure 2.20 MCF-7 ICC controls: A) without primary antibodies but with Alexa 488 or
Alexa 594, nuclear stain (blue) was added; B) with primary antibody for ERα along with
Alexa 594 (red), nucleus (blue). (630x magnification)

2.3.4

Mitochondrial Shapes and Location
Mitochondrial shapes and location were determined as described in 2.2.5.

The live adherent 3T3 cells had long networks of mitochondria which were not
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present in the cancer cell lines examined (Figure 2.21). Live adherent Hs578T
sometimes could make short tubular mitochondria (Figure 2.22). Live adherent
MCF-7 cells had small circular mitochondria throughout the cytoplasm instead
of tubular mitochondria (Figure 2.23).

Figure 2.21 Mitochondria (red): Live mouse 3T3 embryonic fibroblasts grown on
coverslips in atmospheric oxygen. (630x magnification)
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Figure 2.22 Mitochondria (red): Live Hs578T grown on coverslips in atmospheric
oxygen (630x magnification).
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Figure 2.23 Mitochondria (red): Live MCF-7 cells grown on coverslips in atmospheric
oxygen (630x magnification).
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An experiment was done to see if there was a difference in mitochondrial
morphology between adherent cells and trypsinized cells. Trypsinized cells are
round and the mitochondria in these cells were short, swollen, and in clusters
(Figure 2.24).

A

B

Figure 2.24 Mitochondria (red): A) Live trypsinized MDA-MB-468 cell, B) live
trypsinized MCF-7 cell (1000x magnification)

For MDA-MB-468 cells and MCF-7 cells stained with mitotracker red then
fixed there did not appear to be much difference (Figure 2.25). Fixed cells did
not have distinct mitochondria like that found in live cells.
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B

Figure 2.25 Fixed cell staining with mitotracker red: A) MDA-MB-468 cells, and B)
MCF-7 cells (630x magnification)

Mitotracker Red Controls
MCF-7 cells, without mitotracker added, were trypsinized then examined
using a fluorescent microscope to ensure that there was no autofluorescence
(Figure 2.26). No fluorescence was present in these cells.

Figure 2.26 MCF-7 autofluorescence control (630x magnification)
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2.3.5

Cancer Drug Studies
To a patient with cancer the most important thing is treatment.

Cytotoxicity assays are done to screen compounds to look for drugs that can kill
cancer cells. One common cytotoxicity assay is the MTT assay which utilizes
3-(4, 5-dimethylthiazolyl-2)-2, 5-diphenyltetrazolium bromide, short for methylthiazolyl-tetrazolium, added to medium containing cells. MTT is reduced by
viable cells to a water insoluble violet-blue formazan crystal.
Cytotoxicity Results in 96 Well Plates for Normoxia
Crystals were present in media and DMSO samples and once the crystals
were dissolved they produced a dark purple solution. This was true for both
MCF-7 and Hs578T so these cells were alive. There were few to no crystals in the
MCF-7 tingenone or Hs578T tingenone samples (Figures 2.27 and 2.28). In 96
well plates the wells with dead cells are usually clear, light (drug) color, or light
purple once the few crystals present are dissolved (Figure 2.29). For MCF-7 or
Hs578T 0.01% tingenone (1 µl of 1% stock drug in 100 µl media) and 0.01%
sanguinarine killed about 100% of the cells under normal cell culture conditions
while 0.01% doxorubicin killed 100% of the MCF-7 and 90% of the Hs578T cells
in normoxia (Table 2.1). In another experiment with 0.01% doxorubicin there was
approximately 60% kill each for MCF-7 and 578T (Tables 2.2 and 2.3). The
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percent kill varied depending on the plating density for that experiment and the
amount of cells killed by DMSO that experiment also.

A

B

C

Figure 2.27 MCF-7 cells grown in normoxia with A) media (no drug), B) 0.01% DMSO,
and C) 0.01% tingenone (100x magnification)

A

B

C

Figure 2.28 Hs578T cells grown in normoxia with A) media (no drug), B) DMSO, and
C) 0.01% tingenone (100x magnification)
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control columns

Hs578T in 96 well plates with
Tingenone added (orange crystals
= precipitated tingenone) for
48 hours (before MTT added)

different drugs are
in these columns

media without drugs
wells ~4 hours after
MTT has been added

tingenone wells ~4 hours
after MTT has been added
(few to no crystals are
present so cells should be
dead)
Purple wells = crystal are present
Clear wells = few to no crystals present

Figure 2.29 Left: photograph of a well with Hs578T cells and tingenone, Right:
photograph of a partial 96 well plate after formazan crystals have been dissolved.

Table 2.1 Cancer drug compounds tested against cell lines in 96 well plates
"normal" cell line

human breast cell lines

Drug compounds
(stock concentrations)

3T3 (mouse)
%kill

MCF-7
%kill

Hs578T
%kill

MDA-MB-468
%kill

Tingenone (1%)
Doxorubicin (1%)
Doxorubicin (0.1%)
Doxorubicin (0.001%)
Camptothecin (1%)
Camptothecin (0.01%)
Camptothecin (0.001%)
Vinblastine (0.0599µM)
Paclitaxel (0.25µM)

100
97.31

100
100.95

100
87.7

100
100.42

20.1
66.58
20.57
12.19
43.86
50.81

27.63
77.4
73.15
65.24
51.04
57.76

32.41
117.07
56.41
27.49
67.83
90.69

74.28

49.97

* all compounds are dissolved in dimethyl sulfoxide (DMSO)
* wells contain 1µl drug in 100 µl media so a 1% stock drug has 0.01% drug in the well
* % kill is based on sample/DMSO control
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Table 2.2 MCF-7 cells with drug compounds
Extract/Compound
Average Std. Dev. of % Viable
(stock concentrations)
A(570)
A(570)
Medium
1.433
0.009
DMSO
0.956
0.056
66.71
Tingenone
-0.003
0.007
(100nM) caffeine
0.892
0.032
93.34
(1µM) caffeine
0.929
0.062
97.18
(10µM) caffeine
0.981
0.047
102.57
(100µM) caffeine
0.936
0.027
97.89
(1mM) caffeine
0.946
0.038
98.93
(100mM) caffeine
0.765
0.030
80.04
(1%) Doxorubicin
0.414
0.053
43.46
(1%) Sanguinarine
-0.024
0.007
-2.22
(1%) Ellipticine
-0.001
0.012
0.18
(1%) Chelerythrine
0.498
0.062
52.30
(100nM) caff + (1%) Dox
0.802
0.057
83.98
(1µM) caff + (1%) Dox
0.716
0.090
74.97
(10µM) caff+(1%) Dox
0.860
0.011
89.95
(100µM) caff+ (1%) Dox
0.725
0.187
75.92
(1mM) caff+ (1%) Dox
0.886
0.075
92.75
(100mM) caff+ (1%) Dox
0.697
0.050
73.05
(1%) Doxorubicin
0.323
0.075
34.00
(1%) Sanguinarine
-0.019
0.006
-1.69
(1%) Ellipticine
0.001
0.007
0.48
(1%) Chelerythrine
0.399
0.066
41.98
Brenda
1µl caffeine +1µl (1%) Doxorubicin/100µl media per well
rest of wells are 1µl drug/100µl media per well
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% Kill

Std. Dev. of
% Kill

33.29
6.66
2.82
-2.57
2.11
1.07
19.96
56.54
102.22
99.82
47.70
16.02
25.03
10.05
24.08
7.25
26.95
66.00
101.69
99.52
58.02

3.34
6.47
4.91
2.79
3.96
3.08
5.51
0.73
1.23
6.47
5.99
9.42
1.13
19.54
7.87
5.21
7.86
0.58
0.72
6.92

Table 2.3 Hs578T cells with drug compounds
Extract/Compound
Average Std. Dev. of % Viable % Kill Std. Dev. of
(stock concentrations)
A(570)
A(570)
% Kill
Medium
0.764
0.039
DMSO
0.556
0.031
72.79
27.21
Tingenone
-0.043
0.032
(100nM) caffeine
0.510
0.069
92.24
7.76
11.55
(1µM) caffeine
0.554
0.023
99.62
0.38
3.82
(10µM) caffeine
0.510
0.017
92.36
7.64
2.84
(100µM) caffeine
0.503
0.039
91.16
8.84
6.55
(1mM) caffeine
0.554
0.010
99.70
0.30
1.58
(100mM) caffeine
0.434
0.041
79.62
20.38
6.87
(1%) Doxorubicin
0.204
0.043
41.27
58.73
7.15
(1%) Sanguinarine
-0.024
0.005
3.22
96.78
0.86
(1%) Ellipticine
-0.030
0.006
2.25
97.75
0.93
(1%) Chelerythrine
0.024
0.023
11.20
88.80
3.83
(100nM) caff + (1%) Dox
0.470
0.041
85.70
14.30
6.80
(1µM) caff + (1%) Dox
0.458
0.044
83.69
16.31
7.27
(10µM) caff+(1%) Dox
0.459
0.021
83.72
16.28
3.46
(100µM) caff+ (1%) Dox
0.463
0.010
84.46
15.54
1.65
(1mM) caff+ (1%) Dox
0.393
0.087
72.80
27.20
14.54
(100mM) caff+ (1%) Dox
0.339
0.049
63.74
36.26
8.21
(1%) Doxorubicin
0.158
0.028
33.54
66.46
4.65
(1%) Sanguinarine
-0.021
0.005
3.65
96.35
0.78
(1%) Ellipticine
-0.030
0.004
2.21
97.79
0.68
(1%) Chelerythrine
0.106
0.131
24.93
75.07
21.89
Brenda
1µl caffeine +1µl (1%) Doxorubicin/100µl media per well
rest of wells are 1µl drug/100µl media per well
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In Tables 2.2 and 2.3, caffeine was also added to the cells as a drug
compound. In the caffeine plus doxorubicin wells the caffeine, in the
concentrated indicated, was added to the cells for 1 day then the doxorubicin
was added. Either the caffeine protected the cells from doxorubicin killing or
there was not enough time for doxorubicin to kill the cells. This was true for both
MCF-7 and Hs578T cell lines.
To determine how much tingenone is cytotoxic for MCF-7 cells in
normoxia, several experiments were done with tingenone at varying dilutions
(Figure 2.30) then cell death was monitored with MTT or trypan blue. Tingenone
stock concentrations of 1%, 0.1%, 0.01%, 0.001%, and 0.0001% were tested. For
0.01% stock (0.0001% final concentration) tingenone some MCF-7cells were dead
and some were alive. Cells are dead in final concentrations of > 0.0001%
tingenone. There did not appear to be a difference in the results between using
the MTT or the trypan blue to monitor cell death.
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MCF-7 plus tingenone in final concentrations indicated (no MTT added)

0.01%

0.001%

0.0001%

0.00001%

0.000001%

MCF-7 plus tingenone in final concentrations indicated (MTT added)

0.01%

0.001%

0.0001%

0.00001%

0.000001%

MCF-7 plus tingenone in final concentrations indicated (trypan blue added)

0.01%

0.001%

0.0001%

0.00001%

0.000001%

Figure 2.30 MCF-7 plus tingenone in stock concentrations of 1%, 0.1%, 0.01%, 0.001%,
0.0001%: 1% stock → 0.01% drug in the sample.
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Formazan Crystal Formation over Time
Under normal atmospheric oxygen conditions, it was possible to monitor
the progression of crystal formation (Figure 2.31) using the InQ instrument (see
Chapter 3). During crystal formation shrinkage of several cells was noticed. As
the dark areas increase in these cells the cells continued to shrink. A small cell
stopped shrinking in less than one hour of MTT addition. A larger cell continued
to shrink for more than two hours. During the 24 hour MTT assay it was found
that the media turned dark in color and the dark solution could enter the cells
and appeared as dark, contained areas in the cells. After approximately 24 hours
the majority of the cells still had dark areas but there were a few cells that
appeared to be back to normal. Crystal nucleation sites were visible on the
outside of many but not all of the cells and it was possible to watch the crystal
growth over time. Almost all of the cells appeared to have dark areas inside of
them but not all of the cells end up with crystals. After 24 hours in normoxic
conditions very long purple needle crystals were present. The presence of purple
formazan crystals indicated that cells were alive.
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A

B

C

D

E
Figure 2.31 Crystal formation was monitored over a twenty four hour period using the
InQ instrument with normoxic conditions. A) time 0 = MTT just added, B) time = 1 hour
20 minutes after MTT addition, C) time = 2 hours 20 minutes after MTT addition, D) time
= 4 hours after MTT addition, and E) 24 hours after MTT addition. (circles highlight cell
shrinkage, black arrows highlight cells with then later without dark areas)
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Crystal Formation in Various Reagents
Various combinations of PBS, sterile water, RPMI1640, DMEM, and FBS
were added to 96 wells plates and incubated (as described in section 2.2.3) before
MTT was added. Photos were taken at 96 hours of some of the crystals present in
media after reduction of MTT (Figure 2.32). Wells containing only FBS and wells
containing PBS plus 10% FBS had crystals and very high absorbance readings
indicating that reduction had taken place. Yet the media with 10% FBS did not
have such drastic reduction. Apparently the extra salts in the media help to
prevent the reduction from taking place as quickly as in PBS with 10% FBS. But
even so MTT can form tetrazolium crystals without the presence of cells.
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E

A

B

C

D

G

F

Figure 2.32 Reagents versus MTT reduction assay: A) RPMI 1640 pH 7.35, B) RPMI
1640 pH 7.3 + 10% FBS, C) DMEM high glucose pH 7.44, D) DMEM high glucose pH 7.44
+ 10% FBS, E) PBS pH 7.49, F) PBS pH 7.49 +10% FBS, and G) FBS only. (100x
magnification)
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2.4

Discussion
MCF-7, Hs578T, MDA-MB-468, CAMA-1, and mouse 3T3 cells grew and

divided in RPMI 1640 feeding media pH 7.3 under normoxia conditions. MCF-7
and Hs578T cells grew in the range of pH 8.69 to pH 5.98. When MCF-7 cells
were tested further it was found that they can live to at least pH 5.41.
Previous results for western blots for ERα indicated that Hs578T and
MDA-MB-468 breast cancer cells are estrogen receptor negative and MCF-7
breast cancer cells are estrogen receptor positive in normal cell culture conditions
(Neve et al. 2006). In our ICC studies no ERα was present in Hs578T or MDAMB-468 cells but ERα was present in MCF-7 cells. Previous results for western
blots for CA9 and HIF-1α indicated that Hs578T expresses CA9 and HIF-1α and
MCF-7 does not in normal cell culture conditions (Neve et al. 2006). In our ICC
experiments it was found that Hs578T cells had both HIF-1α and CA9 present in
both the cytoplasm and nucleus and MDA-MB-468 cells had HIF-1α and CA9
present in the nucleus. However our results showed MCF-7 cells had HIF-1α
present in the nucleus and CA9 present in the cytoplasm.
Mitotracker red was used to examine the morphology of the mitochondria
in cell lines. For mitochondria the classical image is that of long spaghetti like
structures that form networks (Chiche et al. 2010). Our results showed that in
normoxia the mouse 3T3 fibroblasts do have this classical structure but this was
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not true for the breast cancer cell lines tested. Hs578T had short tubular
mitochondria while MCF-7 had small circular mitochondria and MDA-MB-468
cells had more individual mitochondria located throughout the cytoplasm. The
morphology of the MCF-7 mitochondria found in this research was different
than the morphology found in research done by Chiche et al., in 2010. They said
that their MCF-7 cells had tubular morphology but they did not show a picture
of their MCF-7 cells (Chiche et al. 2010). They used electron micrographs and not
mitotracker red to observe mitochondria morphology in the cells they studied.
Research by Das et al. using mitotracker red in MCF-7 cells had morphology
more like that found in our research (Das et al. 2010).The mitochondrial shapes
for our Hs578T and MDA-MB-468 cells compared to images found in articles by
Palasuberniam et al. and Bose et al. respectively (Palasuberniam et al. 2015; Bose
et al. 2013). For trypsinized cell samples the mitochondria were mostly clustered
together so trypsinized samples should not be used for morphology studies.
Fixed samples did not appear to be as good as live samples for viewing
mitochondria. Live samples are the preferred way to study mitochondrial
morphology and location.
The MTT assay, which is a popular cytotoxicity assay used by many
laboratories, was used to examine the ability of drug compounds to kill cells.
MCF-7, Hs578T, MDA-MB-468, and mouse 3T3 fibroblasts did grow in the
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presence of DMSO but not in the presence of tingenone which was used as a
positive control. The MTT can form formazan crystals immediately when added
to FBS and PBS with 10% FBS even when cells are not present. There was less
crystal formation in the RPMI 1640 feeding media (contains 10% FBS) that was
used in these cell growth experiments.
There are some possible disadvantages to using cell lines for cancer
research. Disadvantages include: 1) cell lines may have changes in genetics,
mRNA, etc.; 2) cell lines may no longer have the tumor heterogeneity that was
present in the primary tumor; 3) cell lines cultured under inappropriate
conditions can influence the cell morphology; 4) cell lines may lose the interrelationships that occurs between cells in the tumor; and 5) cell lines do not
contain components of the tumor microenvironment (Holliday and Speirs 2011;
Wilding and Bodmer 2014). Another disadvantage to using cell lines for cancer
research is that cell lines cultured in normal conditions used by most laboratories
do not represent the hypoxic areas that are present in solid tumors.
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CHAPTER 3

HYPOXIC CELL CULTURE SYSTEM I - INQ

3.1

Introduction
One objective of this research was to determine if hypoxic cell culture

methods could be used to study drug efficacy under conditions that better
matched in vivo conditions in tumors. A hypoxic cell culture method had to be
found. The InQ was just the system needed to culture cells under conditions of
hypoxia. The InQ system (Figure 3.1), a beta unit developed by InQ Biosciences
in Huntsville, Alabama, was used to grow cancer cell lines for days to weeks
under a variety of conditions including the “ideal” culture conditions or under
hypoxia, less than 2% oxygen, which may be closer to conditions found in many
solid tumors. The InQ system was programmed to provide a variety of
temperatures and gas mixtures. Oxygen, CO2, nitrogen or other gas
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concentrations could be injected at different percentages as needed. Once the
temperature and gas mixtures were programmed and the appropriate gas
concentration was achieved then the cassette (Figure 3.2) was filled with cells
and media and then inserted into the InQ. Once the cells have settled to the
bottom of the cassette the photograph locations and time intervals were selected.
Photographs can be taken in the same location at timed intervals from 1 minute
up to 60 minutes. All photos are stored on the hard drive and selected
photographs, temperature and gas ratio data can be emailed to the user. This
allows remote access and monitoring. The InQ system remained closed for the
length of the experiment so there was no temperature change and no
reoxygenation of the cells during cellular monitoring of cell movement, cell
growth, cell division, and other cell activities.
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InQ System
computer
touch screen

Tray inside
the InQ
(this is where
it ejects)

microscope objective
Figure 3.1 The InQ system: the sample cassette is held in place on a tray inside the
instrument.
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Cassette

Figure 3.2 InQ cassette: In the top view each large, square, polystyrene chamber
contains a circular poly-D-lysine coated coverslip. The upper plastic channels contain
extra media. The lower view shows the front of the cassette where the red, circular,
septa are located. The cell culture media is visible in this view.
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3.2

InQ Materials and Methods
The InQ hypoxia experiments require special order cassettes from

InQ Biosystems. These cassettes cost $100 each and they only hold two samples
at a time. A nitrogen gas tank with regulator and an air tank with regulator were
needed in addition to the carbon dioxide gas tank that was normally used in the
laboratory.

3.2.1

Cell Culture in InQ
To set up the InQ instrument the gas lines were connected to ports with

Port 2 for air, Port 3 for CO2, and Port 4 for nitrogen. Pressure from the tanks
registered between 15-20 psi going into InQ. Pressure greater than 20 psi can
damage the InQ. The InQ was turned on by pushing the button on the bottom
right corner of the instrument. The “temperature” screen was selected and the
temperature was set to 36.7°C by using the + / - keys to enter numbers. The
“gases” screen was selected and the percentage for each gas was set. For hypoxia
the InQ was set at Port 2 Air 7% (21% O2 x 7% = 1.47% O2), Port 3 CO2 5%, Port 4
Nitrogen 87%, all with 10 seconds 2 psi delivery rates for gases.
The InQ cassette has 2 chambers each containing a round coverslip coated
with Poly-D-Lysine. This cassette can be used in both normoxic and hypoxic
experiments. Cassettes set up for hypoxic experiments contained 5 to 8 ml media
plus added cells for a concentration of 7x104 to 4x105 cells total in each chamber.
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Once loaded the lids were closed on each chamber and the cassette was ready to
load into the InQ. To eject the tray the “Eject” button was pushed on the
Eject/Load screen. Once the tray was ejected the cassette was carefully inserted
onto the tray making sure it was seated properly. The “Load” button was pushed
and the tray entered the InQ.
Photography was set up by going to the “XY Table” screen. The
microscope/light has to be turned on, the “Live” box checked and then the
backlight was adjusted by using the “+” button until the screen lights up some.
Next the “uScope” screen was selected. Here the area in the cassette chamber to
view and/or photograph was selected. The microscope moved to this location
and that area appeared on the screen in place of the large cassette figure. The
Course/Fine button was used to adjust the focus until the image is in focus. This
process was repeated until all areas were selected for monitoring. “Save Images”
was pushed to save all the images then the “Live” box was unchecked. This was
very important so the light does not stay on and overheat the cells. To select the
times for photographs to be taken and for information to be mailed to the user
the “Experiment Control” screen was selected. The times were selected for both
the time to take and email photos. All collected images were stored in the InQ
and can be retrieved at a later time even if not emailed.
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For most InQ hypoxia experiments cells were grown for 5 to 10 days
depending on cell plating density. The media was not exchanged to allow for
pH changes, decrease in nutrients, increase in waste products, and no addition of
oxygen for the length of the experiment. Cell concentrations were varied
depending on the cell line used and concentration needed for experimental
success. Normoxia controls were set up on coverslips in 6 well plates and placed
in a humidified incubator with 5% CO2 at 36.5 - 37°C. For normoxia (normal
atmospheric conditions) controls in the InQ system the set up included: 1) Air
settings of 20-21% O2 and CO2 5% with 10 seconds 2psi delivery rates for gasses;
and 2) Set Temperature of 36.7°C and 36.7°C for each cassette chamber.

3.2.2

MTT Assay for InQ Hypoxia
The hypoxic cell culture conditions for InQ hypoxia experiments used CO2

5%, nitrogen 88%, air at 7% for 1.4% oxygen levels, and temperatures of 36.5 to
37°C. Cells were loaded as described in the InQ hypoxia section 3.2.1 and then
the cassette was placed in the InQ where it stayed undisturbed for the required
number of days depending on the experiment being done. Media was not
removed nor replaced yet the cells survived, grew, and proliferated. “Drug”
compounds were either added at plating (variation one) with the cells or they
were added after the cells had incubated (variation two) for 2 days (or more
depending on the experimental conditions). At the appropriate time, depending
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on the experiment being conducted, 1 ml of MTT (0.5% stock) solution was
added to each chamber by injecting the solution through the septa without
adding air or removing any media. Incubation was continued in the InQ for 24
hours. Chambers were checked for the presence or absence of crystals and
photographs were taken.

3.2.3

Immunocytochemistry (ICC) in InQ Hypoxia
ICC experiments on coverslips from the InQ cassettes and confocal

microscopy were done following the same procedure as normoxia coverslips (see
2.2.4, 2.2.6).

3.2.4

Mitotracker Red in InQ Hypoxia
Mitotracker red experiments on coverslips from the InQ cassettes and

confocal microscopy were done following the same procedure as normoxia
coverslips (see 2.2.5, 2.2.6).

3.2.5

Photography in InQ
The InQ instrument had an internal phase contrast inverted microscope

with 4X or 10X Objective and Digital Magnification and a camera system.
Photographs were .jpg photographs which were cropped and sized to fit as
needed. Cell images for publishing and printing were processed as normoxic cell
photographs (see 2.2.8).
81

3.2.6

Cell Culture to Mimic Hypoxia
For hypoxia experiments using cobalt chloride (CoCl2) cells were plated in

six well plates which contained 2 ml feeding media per well supplemented with
500 µM CoCl2. Cells were grown for several days until the proper cell density
was achieved. The media was not exchanged to allow for pH changes, decreased
nutrients, and increased waste products for the length of the experiment to
compare with other conditions. The cell line used was MCF-7, an estrogen
receptor positive breast cancer cell line. Results for these cells were compared to
normoxic conditions and to InQ hypoxia conditions.

3.3

InQ Hypoxia Results
The InQ system was used for hypoxia cell growth experiments.

3.3.1

Cell Growth in InQ Hypoxia
Hs578T and MCF-7 grew in hypoxia (1.4% oxygen) conditions. The

Hs578T cells stretch and move about in the cassette chambers. The Hs578T and
MCF-7 cells reproduce like they do in cell culture flasks in a 37°C incubator. In
Figure 3.3 Hs578T cells and Figure 3.4 MCF-7 cells were plated and then
photographs were taken at the same position over several days. On day 1 when
the Hs578T cells were counted there were 43 cells visible in the photographed
area and by day 4 there were 94 cells present. For the MCF-7 cells on day 1 there
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were 19 cells and by day 4 there were 54 cells. Photographs were taken while the
cells were in the InQ using the built-in microscope/camera system of the InQ.
Mouse 3T3 fibroblasts and MDA-MB-468 cancer cells also grew in the InQ under
conditions of hypoxia (Figure 3.5).
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Figure 3.3 Hs578T cells maintained under 1.4% oxygen (hypoxia) in the InQ. The cells
were plated (day 0). A) day 1, 12:19 pm; B) day 2, 12:19 pm; C) day 3, 12:19 pm; D) day
4, 6:19 pm; and E) day 5, 12:19 pm. The dark line present in all the photographs is the
edge of a coverslip. F) graph showing the counts per field of view done from
photographs A-E.
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Figure 3.4 MCF-7 cells maintained under 1.4% oxygen (hypoxia) in the InQ. The cells
were plated (day 0). A) day 1, 9:41 pm; B) day 2, 9:41 pm; C) day 3, 9:41 pm; D) day 4,
9:41 pm; E) day 5, 9:41 pm; and F) graph showing the counts per field of view done
from photographs A-E.
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A

B

Figure 3.5 A) 3T3 cells growing in InQ hypoxia for 2 days, and B) MDA-MB-468 cells
growing in InQ hypoxia for 3 days.

3.3.2

Antibody Results for InQ Hypoxia

ERα in MCF-7
Presence or absence of ERα was determined as described in section 3.2.3.
MCF-7 cells are estrogen receptor positive so they should have a large amount of
ERα present. In InQ hypoxia there was a dramatic decrease of ERα in the
nucleus of the MCF-7 cells (Figure 3.6).
To see if the MCF-7 cells will produce ERα again when reoxygenated,
MCF-7 cells were grown in InQ hypoxia then the media was replaced with fresh
media and incubated in normoxia. ERα was present in the nucleus in these cells
as expected (Figure 3.6 C).
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Figure 3.6 ICC photographs for MCF-7 cells grown on coverslips in: A) normoxia; B)
InQ hypoxia; and C) InQ hypoxia then reoxygenated; A-C) ERα (red), nucleus (blue);
and D) graph showing comparison of ERα percentages
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CA9 and HIF-1α in MCF-7
Presence or absence of CA9 andHIF-1α was determined as described in
section 3.2.3. Three different photographs were used to calculate the quantity of
cells that stained for CA9 and HIF-1α. In InQ hypoxia 88% of the MCF-7 cells had
CA9 in the cytoplasm while 100% of the MCF-7 cells had HIF-α present in the
cytoplasm and in the nucleus (Figure 3.7). In InQ hypoxia there is an increase in
the percentage of CA9 and HIF-1α in MCF-7 cells compared to MCF-7 cells
grown in normoxia (Figure 3.8).
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Figure 3.7 ICC photographs for MCF-7 cells grown on a coverslip in InQ hypoxia: A)
CA9 (green) only; B) CA9 (green), nucleus (blue), and HIF-1 α (red); and C) HIF-1 α
(red) only (630x magnification); D) graphs showing the average number (mean ± SD) per
field of view for MCF-7 cells (purple) photographed that stained for CA9 (green) and
HIF-1α (red); and E) graph showing % of MCF-7 cells with CA9 (green) and HIF-1α (red)
in InQ hypoxia.
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Figure 3.8 ICC photographs comparing MCF-7 cells with CA9 (green), nucleus (blue),
HIF-1 α (red): A) normoxia cell growth; B) hypoxia cell growth; and C) graph showing %
of MCF-7 cells with CA9 (green) and HIF-1α (red) in normoxia compared to InQ hypoxia.
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CA9 and HIF-1α in Hs578T
Presence or absence of CA9 andHIF-1α was determined as described in
section 3.2.3. Five different photographs were used to calculate the quantity of
cells that stained for CA9 and HIF-1α. Under InQ hypoxia Hs578T cells had 92%
HIF-1α and 85% CA9 in both the nucleus and the cytoplasm after growth in
hypoxia (Figure 3.9). In InQ hypoxia there is an increase in the percentage of
HIF-1α in Hs578T cells compared to Hs578T cells grown in normoxia (Figure
3.10).
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Figure 3.9 ICC photographs for Hs578T cells grown on a coverslip in InQ hypoxia: A)
CA9 (green) only; B) CA9 (green), nucleus (blue), HIF-1 α (red); C) HIF-1 α (red) only
(630x magnification); D) graphs showing the average number (mean ± SD) per field of
view for Hs578T cells (purple) photographed that stained for CA9 (green) and HIF-1α
(red); and E) graph showing % of Hs578T cells with CA9 (green) and HIF-1α (red) in InQ
hypoxia.
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Figure 3.10 ICC photographs comparing Hs578T cells with CA9 (green), nucleus (blue),
HIF-1 α (red): A) normoxia growth; B) InQ hypoxia growth; and C) graph showing % of
Hs578T cells with CA9 (green) and HIF-1α (red) in normoxia compared to InQ hypoxia.
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CA9 and HIF-1α in MDA-MB-468
Presence or absence of CA9 andHIF-1α was determined as described in
section 3.2.3. One photograph was used to calculate the quantity of cells that
stained for CA9 and HIF-1α. Under InQ hypoxia MDA-MB-468 cells had 67%
CA9 present in the cytoplasm and had 100% HIF-1α present in the cytoplasm
and nucleus after hypoxic growth (Figure 3.11). In InQ hypoxia there is a
decrease in CA9 but the same percentage of HIF-1α in MDA-MB-468 cells
compared to MDA-MB-468 cells grown in normoxia (Figure 3.12).
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Figure 3.11 ICC photographs for MDA-MB-468 cells grown on a coverslip in InQ
hypoxia: A) CA9 (green) only; B) CA9 (green), nucleus (blue), and HIF-1 α (red); C)
HIF-1 α (red) only (630x magnification); D) graphs showing the number per field of view
of MDA-MB-468 cells (purple) photographed that stained for CA9 (green) and HIF-1α
(red); and E) graph showing % of MDA-MB-468 cells with CA9 (green) and HIF-1α (red)
in InQ hypoxia.
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Figure 3.12 ICC photographs for MDA-MB-468 cells with CA9 (green), nucleus (blue),
HIF-1 α (red): A) normoxia growth; B) hypoxia growth and C) graph showing % of
MDA-MB-468 cells with CA9 (green) and HIF-1α (red) in normoxia compared to InQ
hypoxia.
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CA9 and HIF-1α Cell Line Comparison in InQ Hypoxia
In InQ hypoxia there is a difference in the CA9% and HIF-1α% found in the breast
cancer cell lines as shown in Figure 3.13.

Comparing InQ Hypoxia Percentages
100
90
80
70
60
50

% of cells with CA9

40

% of cells with HIF-1α

30
20
10
0
InQ hypoxia
MCF-7

InQ hypoxia InQ hypoxia
Hs578T
MDA-MB-468

Figure 3.13 Comparison of CA9% and HIF-1α% between 3 breast cancer cell lines: CA9
(green) and HIF-1α (red) in InQ hypoxia.

3.3.3

Cell Culture Supplemented with Cobalt Chloride
MCF-7 cells were placed in media supplemented with 500 µM cobalt

chloride (CoCl2). ICC with antibodies to ERα, HIF-1α, and CA9 were done to see
if cobalt chloride could provide a hypoxia environment. In CoCl2 experiments
10% of the MCF-7 cells had CA9 present in the cytoplasm and 70% had ERα
present in the nucleus (Figure 3.14). In another experiment 88% of the MCF-7
cells had HIF-1α present in the nucleus and 25% had CA9 present in the
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cytoplasm (Figure 3.15). Cobalt chloride experiments did not compare to InQ
hypoxia experiments.
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Figure 3.14 ICC photographs for MCF-7 cells: A) cobalt chloride used in the media to
mimic hypoxia, ERα (red) in the nucleus (blue)and CA9 is in the cytoplasm (green); B)
same as A but with the blue nucleus and green CA9 removed from the photograph (630x
magnification); and C) graph showing the CA9% and the ERα% in normoxia compared
to the CA9% and the ERα% in cobalt chloride supplemented media.
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Figure 3.15 ICC photographs for MCF-7 cells: A) cobalt chloride used in the media to
mimic hypoxia, HIF-1α (red) in the nucleus (blue) and the CA9 is in the cytoplasm
(green); B) same as A but with the blue nucleus and green CA 9 removed from the
photograph (630x magnification); and C) graph showing the CA9% and the HIF-1α% in
normoxia compared to the CA9% and the HIF-1α% in cobalt chloride.
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3.3.4

Mitochondria Morphology in InQ Hypoxia
Mitochondrial shapes and location were determined as described in 3.2.4.

To test to see if mitochondrial changes can indicate hypoxia in live cells several
experiments were set up and the results were compared. MCF-7 cells (Figure
3.16) and Hs578T cells (Figure 3.17) were grown in the InQ under conditions of
hypoxia. The mitochondria appeared to be small, individual, and located
throughout the cytoplasm.

Figure 3.16 Mitochondria (red): Live MCF-7 cells grown in InQ hypoxia. (630x
magnification)
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Figure 3.17 Mitochondria (red): Live Hs578T grown in InQ hypoxia. (630x
magnification).

3.3.5

Formazan Crystal Formation in InQ Hypoxia
The MTT cytotoxicity assays that were done in the InQ cassette under

hypoxia conditions gave unexpected results. For cells in media (without drug
compounds) under hypoxic conditions there were short, purple, needle crystals
present throughout the cassette chamber. When the media was removed so the
crystals could be dissolved it was noticed that the many of the crystals and cells
came out with the media. When the crystals were dissolved and the absorbance
was read the optical density (OD) was extremely high and dilutions had to be
done to get the final absorbance reading.
To see if this high absorbance was due to the cell density an experiment
was done with many cells in one well and with few cells in the other well.
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Hs578T cells (many cells) formed many purple crystals and MCF- cells (few cells)
formed few purple crystals (Figure 3.18) yet both cell lines had purple media and
the absorbance readings were still very high and had to be diluted to get a final
reading.
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A

B

C

D

Figure 3.18 A) Hs578T cells grown in InQ hypoxia then MTT solutions was added, B)
Hs578T photographs were taken approximately 24hrs after MTT addition, and C ) MCF7 cells grown in InQ hypoxia then MTT solutions was added D) and MCF-7 photographs
were taken approximately 24hrs after MTT addition .
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To see if the hypoxia conditions were influencing the MTT, a cassette was
loaded with Hs578T cells and MCF-7 cells both treated with 1% (stock
concentration) tingenone to kill the cells. It was found that a few crystals were
formed but for the most part the media was very purple (Figure 3.19). Either the
tingenone does not kill these cells in hypoxia or hypoxia is affecting the MTT
assay.

A

A

C

B

Figure 3.19 MTT assay done in InQ cassette under hypoxia (1.4% oxygen) for 24 hours:
A) media/tingenone/MTT solution was removed from the hypoxic cassette and placed in
a cuvette, B) Chamber A containing MCF-7 cells, and C) Chamber B containing Hs578T
cells.
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Formazan Crystal Formation in Various Reagents in Hypoxia
To see if the media or other cell culture reagents can reduce MTT in
hypoxia, experiments were set up in various solutions with and without cells. In
experiments with cells, where incubation times were varied from 36 hours to
96 hours before adding MTT, time intervals did not change the results. Hypoxic
media with cells still turned purple when MTT was added to the sample (Table
3.1).

Table 3.1 MTT crystal formation in reagents under hypoxia
incubation
time

pH

hypoxia

(before MTT)

PBS + FBS
PBS + FBS
RPMI + FBS

tetrazolium

formazan

formazan

salt (yellow)

(Purple soln)

crystals
(4-24 hrs)

x
x
x

x
x
x

36hrs
48hrs

7.4
7.4

hypoxia
hypoxia
hypoxia

48hrs

7.4

hypoxia

x

x

96 hrs

7.4

hypoxia

x

x

RPMI + FBS +
MCF-7 +
tingenone

96 hrs

7.4

hypoxia

x

x

RPMI + FBS +
Hs578T +
tingenone

96 hrs

7.4

hypoxia

x

x

RPMI + FBS +
MCF-7
RPMI + FBS +
Hs578T
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3.4

InQ Hypoxia Discussion
Specifications for the InQ beta unit and verification of the oxygen levels in

the InQ were provided by InQ Biosystems (Appendix A). The ability for the InQ
unit to provide conditions of hypoxia was verified.
MCF-7, Hs578T, MDA-MB-468, and mouse 3T3 cells did grow and divide
in RPMI 1640 media pH 7.3 under InQ hypoxia conditions. Protein markers such
as CA9 and HIF-1α were used with ICC to determine if hypoxia was achieved in
the cells. CA9 has been used by many researchers as a hypoxia marker since
most normal cells express no CA9 but under hypoxia there is an increase in CA9
(Kaluz, Kaluzova, and Stanbridge 2006). MCF-7, Hs578T, and MDA-MB-468 all
had an increase in CA9 in InQ hypoxia. One of the major proteins produced
during hypoxia is HIF-1 (hypoxia-inducible factor 1). Most normal cells
express little to no HIF-1α but under hypoxia there is an increase in HIF-1α
(Kaluz, Kaluzova, and Stanbridge 2006). MCF-7, Hs578T, and MDA-MB-468 all
had an increase in HIF-1α in InQ hypoxia.
The loss of ERα in cells that are normally ER positive is an indicator of
hypoxia (Park et al. 2009). ERα positive breast cancer cell lines, MCF-7, T47D, and

CAMA-1, were grown under hypoxic conditions (1% O2) after which there was a
decrease in ERα protein compared to normoxic cells, as well as an increase in HIF-1α
protein levels (Kronblad et al. 2005). This compared to the results found with MCF-7
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cells in the InQ under hypoxia. In InQ hypoxia the MCF-7 (normally ER positive)
cells had a dramatic decrease in ERα. This decrease in ERα in MCF-7 cells and
increase in CA9 and HIF-1α in MCF-7, Hs578T, and MDA-MB-468 all indicate
that hypoxia conditions were present. For MCF-7 cells grown with cobalt
chloride the HIF-1α was present in the nucleus and CA9 was present in the
cytoplasm of a few but not all cells. ERα was present in the nucleus of the MCF-7
cells grown in the presence of cobalt chloride. This does not compare to InQ
hypoxia ERα results.
Due to reduction of MTT in reagents without cells and to the unexpected
results in hypoxia, MTT may not be the best cytotoxicity assay to use for hypoxic
cells. More experiments comparing MTT and trypan blue should be done to see
which if either is best for cytotoxicity assays in hypoxia.
The InQ was a great instrument to use for growing and testing cells under
conditions of hypoxia. One disadvantage to the InQ was that to view cells under
a higher magnification the cassettes had to be removed from the InQ which
allowed for reoxygenation to take place. Unfortunately, the company went out of
business so there were no updates for the instrument and more importantly there
were no sample cassettes available for use. A new method for hypoxia cell
culture had to be found.
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CHAPTER 4

HYPOXIC CELL CULTURE SYSTEM II - gCVSL

4.1

Introduction
Since the InQ hypoxia system was no longer available for use to culture

cells, a new method needed to be devised to culture cells in reduce oxygen for
long term hypoxia cell experiments. The hypoxic tumor environment is similar to
the ischemic environment with low blood flow, low oxygen, increased metabolic
wastes, low pH, and low nutrient availability. One method that was used to
study ischemia was developed by Pitts et al., in 2004. Their method utilized
confluent, contracting, rat neonatal cardiac myocytes which they covered with a
coverslip and then observed the covered and uncovered cells to see if changes
occurred (Pitts and Toombs 2004). They determined that the coverslip created a
barrier to media diffusion, resulted in rapid hypoxia, and allowed locally
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concentrated metabolic wastes to accumulate (Pitts and Toombs 2004). If this
method resulted in hypoxia then it could be modified for culturing cancer cells.
This led to the development of the gradient coverslip (gCVSL) method (Figure
4.1). The gCVSL method consists of plating cells between two coverslips which
are then placed in a plate containing media. The gCVSL method can more
closely mimic the reduced oxygen, decreased pH, decreased nutrients, and
increased waste environment than the normal cell culture methods. Using this
gCVSL method cell growth and morphology were evaluated while keeping cells
under reduced oxygen conditions. Drug compounds were added to the gCVSL to
look for cytotoxic compounds that will kill cells in anoxia regions, hypoxia
(severe/mild) regions, and normoxia regions. The gCVSL was tested and the
results were compared to the InQ hypoxia instrument to verify that the gCVSL
had regions of hypoxia.
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oxygen
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cells, some diffusion
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to no diffusion,
hypoxic or even anoxic
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Figure 4.1 gCVSL: A) Diagram from the top of the gCVSL; the center region is depicted
in yellow, the mid region is between the center and the dashed line, and the edge region
is outside of the dashed line but still underneath the coverslip; B) On the left is a
drawing from the side of the gCVSL. The cells (shown in yellow) are placed between 2
coverslips (black lines) and the media (shown in pink) is added to the petri dish (blue
outline). On the right is a drawing from the top of an enlarged view of the cells between
the coverslips after incubation. The dark gray cells represent anoxic/hypoxic cells while
the light gray cells represent the hypoxic cells. The green cells are cells that receive
signals from hypoxic cells while still having some diffusion from outside the coverslip.
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4.2

Materials and Methods for gCVSL
The materials needed for gCVSL can be found in most laboratories or

purchased with minimal expense. The coverslips used were Fisherbrand
Microscope coverglass, 22 x 22 x 1.5, 10 oz. (Fisher number 12-541B) along with
either 6 well flat bottom plates (Fisher number 07-200-83) or small petri dishes.

4.2.1

gCVSL procedure
All gCVSL experiments were carried out in a laminar flow hood. All

uncoated glass coverslips were stored in 70% ethanol to sterilize them before use.
Coverslips were removed from alcohol and placed on a kimwipe to allow the
ethanol to evaporate. A 6 well plate was labeled and opened for use. A dry
coverslip was placed in each well then 4 µl of cells in feeding media was placed
in the center of each coverslip. A second dry coverslip was placed on top of the
cells and pressed down gently without adding bubbles. One to 2 ml of feeding
media was pipetted on top of the coverslip and allowed to spread into the well
for each of the 6 wells. The dish was placed in the incubator at 36.5°C with 5%
CO2 to incubate for the time period of the experiment. For normoxia controls the
same procedure was followed except that the second coverslip was not added on
top of the first coverslip. For all experiments the media was not changed every
other day. By not changing the media the cells can communicate with each other,
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pH can change, and waste products can start to accumulate which more closely
simulates the hypoxia experiments.

4.2.2

gCVSL Variations
Many variations can be done for these gradient coverslip experiments.

Cell densities can be varied such that diffusion coefficients will be affected (i.e.,
more cells give decreased diffusion whereas lower cell density allows more
diffusion). Many different pH variations can be tried in the starting media and
pH can be changed as needed anytime during the experiment. Glass coverslips
were used without coating to avoid expense. If cells have problems growing on
untreated coverslips then the glass can be coated with D-poly-lysine or other
substances as long as it does not interfere with fluorescence experiments. If there
is a concern that cells are escaping from between the coverslips to proliferate on
top of the coverslip then an extra coverslip can be placed on top. When it is time
for testing the extra top coverslip can be removed and then the remaining cells
on the coverslips will be hypoxic/anoxic. To increase cell volume multiple
gCVSL coverslip groups can be placed in the same large petri dish. This ensures
the same media conditions to all the cells. Coverslip size can be varied to give
more or less area for cell growth. Coverslip weight can help to keep coverslips in
place. Coverslips can be held in place by adding a thin layer of vasoline (or
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similar compound) to one or two corners of one of the coverslips. Care must be
taken when adding cells and the second coverslip.

4.2.3

Diffusion tests
To demonstrate if liquid could diffuse in to and out from between the

coverslips, a 4 µl drop of methylene blue dye was placed on top of a coverslip
then covered with a second coverslip. Then 2 ml of water was added to the dish
and allowed to set for 17.5 hours at room temperature to see if diffusion would
take place and results were noted. To see if it would continue the water was
removed and fresh water was added to the dish and results were noted.

4.2.4

Trypan Blue Staining
Cell viability was observed using trypan blue assays. Trypan blue

experiments were done with two variations to the original experimental set up.
For variation one, 2 µl of cells in feeding media was placed in the center of the
coverslip then 2 µl of trypan blue was added to the cell drop before placing the
second coverslip. For variation two, the cells were plated, allowed to grow until
the cell density for the experiment was reached, then 600 µl trypan blue was
added to the well to mix with the feeding media. This allowed the trypan blue to
diffuse to the cells over time. For variation three, the cells were trypsinized,
rinsed, then placed in small amount of media plus drug in a tube and incubated
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at 37°C for 24 hours to kill the cells then the dead cells were plated along with
trypan blue for 48 hours. This variation acted as a positive control for trypan blue
staining. All methods were done and compared by observing cells under the
phase contrast microscope.

4.2.5

MTT Assay for gCVSL
For cancer drug studies compounds can be added to the cells at plating

(variation one) before adding the coverslip to ensure that the compound gets to
the center region of the gCVSL or compounds can be added to the media and
allowed to diffuse (variation two) to the center region after the cells have
attached and started to divide. The procedure for diffusion of drugs was done by
plating the cells as done for gCVSL with 2 ml feeding media in the well (day 0).
The cells were allowed to divide for 2 days (or more) until the cell density was
adequate. The drug compound or control compound was carefully added to the
well (day 2). Tingenone was used as a positive control for killed cells while
media and DMSO were used as controls for cell growth. After 2 days with a
drug compound the MTT solution (400 µl) was carefully added to each well
without removing the drug/media (day 4). The plate was incubated for 4 hours,
checked for crystal formation, and then incubated again for approximately 20
hours. After 24 hours, the wells were checked for additional crystal formation.
Photography was done at 4 hours and 24 hours. For the gCVSL method, crystal
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formation in the center region of the coverslip, at the edge region of the
coverslip, and midway between the two regions was monitored and recorded. In
the gCVSL experiments the crystals were not dissolved.
For normoxia coverslip MTT assays (to be set up at the same time as the
gCVSL diffusion experiment) cells were placed on coverslips (day 0) in media
(2ml) and allowed to grow for 2 days. When the drug compounds or control
compounds were added to the gCVSL experiments then the same drug
compound was added to these wells. Tingenone was used as a killing control
while media and DMSO were used as controls for cell growth. After 2 days with
drug compound the MTT solution (400 µl) was carefully added to each well
without removing drug/media. The plate was incubated for 4 hours, checked for
crystal formation, and then incubated again for 20 hours. After 24 hours, check
for additional crystal formation. Photography was done at 4 hours and 24 hours.
These results were compared with the gCVSL results for the same cell line and
drug compound.
Most of the natural drug products used in the MTT assays started at a
concentration of 1% compound in 100% DMSO. This 1% drug compound was
then diluted as needed. In variation two, 20 µl of drug compound was added to
the media (2 ml) in the dish for gCVSL hypoxia and their normoxia controls.
Drug compound concentrations were adjusted as needed for experiments.
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4.2.6

Immunocytochemistry (ICC) in gCVSL
Cells were grown for the appropriate time period using the gCVSL

method along with normal controls. For fixed staining, once the cells have
grown, the normoxia coverslips were rinsed and fixed then methods in 2.2.4 and
2.2.6 were followed. The 2 coverslips for the gCVSL experiments were quickly
separated rinsed, fixed, and methods in 2.2.4 and 2.2.6 were followed. This
provides 2 “hypoxia” samples for each experiment.

4.2.7

Mitotracker Red in gCVSL
Mitotracker red experiments using the gradient coverslip method were

done with several variations to the original experimental set up. For variation
one, 2 µl of cells in feeding media were placed in the center of the coverslip then
2 µl of mitotracker red working solution were added to the cell drop before
placing the second coverslip. For variation two, the cells were plated between the
coverslips then 1 µl of 1mM stock Mitotracker Red was added and allowed to
mix with the feeding media. This allowed the mitotracker red to diffuse to the
cells over time. Results for both methods were done and compared by observing
cells under the microscope. Another variation of Mitotracker red experiments
was done using one of the variations of the live cell experiments, but the cells
were then fixed and observed for mitochondrial morphology.

117

4.3

gCVSL Results
A variety of tests were performed on the gCVSL to determine if this

method could be used for cell culture and to determine if the gCVSL method
could achieve regions of hypoxia and/or anoxia.

4.3.1

Volume between Two Coverslips
The first thing determined in the gCVSL experiment was how much

cell/media volume should be placed between the two coverslips. In the new
gCVSL experiments the media volume under the coverslip was definitely less
than what was available to the cells grown in normoxia on top of the coverslip.
Using a 22 mm x 22 mm x 1.5 mm coverslip in a 35 mm x 10 mm petri dish and
assuming a 9.8 ± 2.6 μm thin film height, as determined by Pitts et al., the gCVSL
has a volume of 4.7 μl between the two coverslips. To test this 5 μl cells in media
was placed on a coverslip and a second coverslip was added. This resulted in
media coming out from underneath the top coverslip, so 4 μl cells in media was
determined to be better and this corresponds with the 9.8 μm thin film height.

4.3.2

Diffusion between Two Coverslips
To demonstrate if liquid could diffuse in to and out from between the

coverslips, a 4 µl drop of methylene blue dye was placed in gCVSL instead of
cells (Figure 4.2). Water was added to the wells in place of media so that color
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from the dye could be seen. Without the presence of cells, fluid will diffuse
between the two coverslips. When cells are added the diffusion will be limited
by the cell numbers as the cells proliferate.
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Figure 4.2 Diffusion of liquid in the gCVSL.
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Oxygen diffusion to cells through media in normal cell culture conditions
was shown to vary by 4-5% (Pettersen et al. 2005). Oxygen levels that started at
19% in the headspace decreased to about 14% at the cell surface (Pettersen et al.
2005). In gCVSL, it is unknown what the exact percentage oxygen is between the
coverslips.

4.3.3

Cell Proliferation in gCVSL
MCF-7, Hs578T, MDA-MB-468, mouse 3T3 fibroblasts (Figures 4.3), and

CAMA-1 cells (Figure 4.4) were grown in gCVSL. MCF-7 cells grew and
attached like normal on the edge and in the mid region of the gCVSL area. In the
center region after several days of growth the cells started to round. CAMA-1
cells appeared to show similar growth patterns as MCF-7 cells. Hs578T, MDAMB-468, and mouse 3T3 cells grew and attached like normal on the edge, in the
mid, and in the center region of the gCVSL area.
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A

B

C

D

Figure 4.3 A) Hs578T cells 2 days after plating in the center region of the gCVSL, B)
MCF-7 cells 2 days after plating in the center region of the gCVSL C) MDA-MB-468 cells
2 days after plating in the center region of the gCVSL (fuzzy line was a scratch to mark
the center), D) 3T3 cells 4 days after plating in the center region of the gCVSL, (all
photographs are 100x magnification)
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Cell Viability over Time in gCVSL
To determine how long cells can survive in gCVSL, experiments were set
up and placed in the incubator at 37°C and left for greater than 1 week. In gCVSL
at 21 days the CAMA-1 cells were mostly rounded in the center region though a
few were still attached but the mid to edge region has live, attached cells (Figure
4.4). At 16 days MDA-MB-468 cells have cells that were attached in the mid
region but there were many more in the edge region (Figure 4.5). For MCF-7 cells
at 12 days the center region has many rounded cells (Figure 4.6). It is not known
whether this region is anoxic, or the pH has dropped too low, or whether the
adhesion proteins were lost. Along the edge regions the MCF-7 cells were
present and proliferating as normal. All the cell lines tested continued to remain
viable as long as the media was present. Photography was done for the gCVSL
experiment without removing the coverslip to prevent reoxygenation.
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A

B

Figure 4.4 CAMA-1 growing for 21 days in gCVSL: A) center region, and B) mid to
edge region (all photographs are 200x magnification)

A

B

C

Figure 4.5 MDA-MB-468 growing for 16 days in gCVSL: A) center region, B) mid
region, C) edge region (all photographs are 100x magnification)
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A

B

Figure 4.6 MCF-7 growing for 12 days in gCVSL: A) center region, B) edge region (all
photographs are 100x magnification)

Evaluation of cell viability over time was performed using trypan blue
added to MCF-7 or Hs578Tcells at plating (variation one). MCF-7 (Figure 4.7)
and Hs578T (Figure 4.8) cells appeared to be alive (did not take up trypan blue)
when grown in gCVSL conditions. This was true for the majority of the center
cells, mid cells, and edge cells over 3hrs, 24hrs, 48hrs, and 96hrs.
To verify that these cells were alive at 24hrs, 48hrs, and 96hrs and not that
the dye had just diffused out a group of experiments were done with pre-killed
MCF-7 or Hs578T cells using variation three (Figures 4.7 D and 4.8 D). Nonviable cells were blue and the blue color did not diffuse out of the cells (center
gCVSL) during the 48hr incubation period.
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Figure 4.7 Trypan blue and MCF-7 cells: A) center, B) mid, and C) edge regions of
gCVSL; D) center region of gCVSL with pre-killed MCF-7 cells plated with trypan blue
for 48 hours; E) timeline for photographs A-C; F) timeline for photograph D
(photographs are 100x magnification)
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Figure 4.8 Trypan blue and Hs578T cells: A) center, B) mid, and C) edge regions of
gCVSL; D) center region of gCVSL with pre-killed Hs578T cells plated with trypan blue
for 48 hours; E) timeline for photographs A-C; F) timeline for photograph D
(photographs are 100x magnification)
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Cells will proliferate in the gCVSL method. The length of time they will
continue depends on the cell line used and the initial plating density. MDA-MB468 cells were plated in gCVSL in a small petri dish and allowed to sit for 1
month at which time the media was drying up. Cells should be dying especially
along the edge of this gCVSL experiment. Trypan blue staining (variation two)
was done on these cells (Figure 4.9). There were blue cells (dead) but surprisingly
there were also clear cells (live) present. This experiment showed that trypan
blue can diffuse to the center region of the coverslip within 48 hours (results
were not checked before 48 hours).
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Figure 4.9 Trypan blue and MDA-MB-468 cells: A) center, B) mid to edge, C) edge (the
line is the edge of the coverslip); D) timeline for A-C (photographs are 200x
magnification )
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Coverslip Variations in gCVSL
To see if the glass coverslips were adequate for cell growth in gCVSL
several experiments were preformed. Experiments with glass coverslips with or
without poly-D-lysine were used. Cells were added and observed using the
phase contrast inverted microscope. Cells did attach and proliferate on noncoated glass coverslips as well as coated glass coverslips (Figure 4.10).

A

B

Figure 4.10 Hs578T cells in gCVSL 24 hours after plating: A) poly-D-lysine coated
bottom coverslip B) non-coated bottom coverslip. (all photographs are 100x
magnification)

In other experiments a very thin film of vasoline (petroleum jelly) was
applied to two opposite corners on one of the coverslips to help prevent
coverslips from sliding apart. The vasoline did not prevent cell growth (Figure
4.11). It did allow for coverslips to be separated when needed for staining.
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Figure 4.11 Drawing of a gCVSL coverslip with Vasoline on two corners (not to scale):
Photograph of Hs578T cells grown in the center region of gCVSL.

4.3.4

Antibody Results in gCVSL

ERα in MCF-7
Presence or absence of ERα was determined as described in section 4.2.6.
Experiments were done in gCVSL using MCF-7 cells to see if the ERα would
disappear as is expected if the cells are hypoxic. In the center region of the
gCVSL there was a decrease of ERα staining in the nucleus of MCF-7 cells
(Figure 4.12).
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A

B

Figure 4.12 ICC photographs for MCF-7: A) MCF-7 gCVSL center: ERα (red), nucleus
(blue); B) same as photograph A except that the blue nucleus was removed from the
photograph. (630x magnification)

To see if coated slides or coated coverslips would make any difference in
these experiments poly-lysine coated (PolysineTM) slides were used with MCF-7
cells and ERα ICC stain. The results were similar to previous ERα done in the
InQ under hypoxia. The ERα was definitely decreased in the center, mid, and
edge regions of the gCVSL (Figure 4.13). The bitmap, for the cells grown in the
center region of the gCVSL, showed strong blue color for the nucleus and tiny
less intense red color for ERα. If ERα was present it was located mostly in the
cytoplasm. The coated slide did not appear to provide any advantage for
hypoxia.
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A

B

C

D
Figure 4.13 ICC photographs for MCF-7 cells that were grown on slides coated with
polylysine then covered with a coverslip to provide the hypoxic environment on the
slide: A) center region, B) mid region, and C) edge region D) bitmap for the center
region (630x magnification)
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To test to see how long it take for each region (center, mid, edge) to
become hypoxic MCF-7 cells were cultured in gCVSL then cells were fixed after 6
hours growth, 24 hours growth, and 48 hours growth. Staining was done to look
for the presence or absence of ERα (Figure 4.14). At 6 hours ERα was still
present in the nucleus of the center region and along the edge ERα was heavier
in the cytoplasm. At 24 hours ERα was decreased in the center. At the edge
region after 24 hours ERα was present to a small extent in the cytoplasm but it
was less than was there at 6 hours. At 48 hours ERα was still decreased in the
center and edge regions. Figure 4.15 shows the graphs for short term and long
term ERα experiments in MCF-7 cells. Based on most of the experiments done
with the MCF-7 cells it appears that it was best to wait at least 24 hours for cells
to become hypoxic in gCVSL.
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Figure 4.14 ICC photographs for MCF-7 cells grown under gCVSL conditions: Red is
ERα and blue is the nucleus. A) 6 hours ERα in the center region, B) 6 hours ERα at the
edge region, C) 24 hours in center region, D) 24 hours at the edge region, E) 48 hours
ERα the center region, and F) 48 hours ERα at the edge region. (630x magnification)
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Figure 4.15 Graphs of ERα (red) and CA9 (green) for MCF-7 grown in gCVSL: A) under
short term hypoxia, B - C) under long term hypoxia.

Reoxygenation of MCF-7
MCF-7 cells were grown in gCVSL to ensure that hypoxia was achieved
and to ensure that cells had time to experience hypoxia. The top coverslip was
removed and the cells were allowed to grow in normoxia before ICC was
performed. The ERα is present again after reoxygenation (Figure 4.16).
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Figure 4.16 MCF-7 cells grown in hypoxic conditions then reoxygenated: ERα (red),
nucleus (blue).

CA9 and HIF-1α in MCF-7
Presence or absence of CA9 and HIF-1α was determined as described in
section 4.2.6. In the gCVSL (Figure 4.17) after 6 day growth of MCF-7 cells, the
center region had increased CA9 in the cytoplasm while HIF-α was present in the
cytoplasm and increased in the nucleus. The mid region had CA9 present in the
nucleus and increased CA9 in the cytoplasm while HIF-α was present in the
cytoplasm and increased in the nucleus. The edge region had CA9 present in the
cytoplasm and HIF-1α present in the nucleus. These results showed that the
gCVSL did have different gradient areas which can affect cellular results just like
a tumor.
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Figure 4.17 ICC photographs for MCF-7 cells grown in gCVSL: A - C) center region; D F) mid region; G - I) edge region; Red is HIF-1α, blue is the nucleus, and green is CA9
(630x magnification); J) Graph for %CA9 and %HIF-1α for MCF-7 cells in gCVSL.
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To check to see if vasoline interfered with ICC samples or not several
gCVSL experiments were conducted such that some coverslips had vasoline on
two corners while others did not. In Figure 4.17, the mid sample had vasoline on
two corners of the coverslips while the center and edge samples did not. Results
for these and other experiments (photographs not shown) compared such that
the use of vasoline did not cause any problems for ICC or cell growth.
CA9 and HIF-1α in Hs578T
Presence or absence of CA9 and HIF-1α was determined as described in
section 4.2.6. In the gCVSL center, mid, and edge regions, the Hs578T cells had
increased CA9 in both the nucleus and the cytoplasm and increased HIF-1α in
both the nucleus and the cytoplasm after 5 days growth (Figure 4.18). These
results showed that the Hs578T cells in gCVSL did have an increase in the
hypoxia markers.
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Figure 4.18 ICC photographs for Hs578T cells grown in gCVSL: A - C) center region; D
- F) mid region; G - I) edge region; Red is HIF-1α, blue is the nucleus, and green is CA9
(630x magnification); J) Graph for %CA9 and %HIF-1α for Hs578T cells in gCVSL.
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CA9 and HIF-1α in MDA-MB-468
Presence or absence of CA9 and HIF-1α was determined as described in
section 4.2.6. In gCVSL center for MDA-MB-468 cells grown for 11 days, there
was an increase of CA9 and HIF-1α in the cytoplasm (Figure 4.19). The same
was true for the mid and edge regions. The increase in cytoplasmic CA9 and
HIF-1α indicated hypoxia was achieved in the gCVSL.
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Figure 4.19 ICC photographs for MDA-MB-468 cells grown in gCVSL: A - C) center
region; D - F) mid region; G - I) edge region; Red is HIF-1α, blue is the nucleus, and
green is CA9 (630x magnification); J) Graph for %CA9 and %HIF-1α for MDA-MB-468
cells in gCVSL.
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ERα, CA9, and HIF-1α comparisons in MCF-7, Hs578T, and MDA-MB-468
In normoxia and hypoxia MCF-7, Hs578T, and MDA-MB-468 have
differences in the presence or absence of protein levels for CA9, HIF-1α, and ERα
(Table 4.1). There was CA9 and HIF-1α present in all the hypoxic cells in InQ and
gCVSL. The gCVSL has 100% CA9 and HIF-1α in cells from all 3 cell lines while
the InQ hypoxia experiments have some differences. Graphs comparing the CA9
and HIF-1α in the InQ and the gCVSL are found in Figure 4.20. The graphs, in
Figures 4.21 and 4.22, compares the CA9 (Figure 4.21 A), ERα (Figure 4.21 B), and
HIF-1α (Figure 4-22), in normoxia, InQ, and gCVSL for all three cell lines. There
is an increase in CA9 and HIF-1α in MCF-7 and Hs578T cells in gCVSL when
compared to normoxia. The MDA-MB-468 CA9 and HIF-1α levels stayed the
same in normoxia compared to gCVSL. In InQ hypoxia and gCVSL hypoxia the 3
breast cell lines all compare in that there was no ERα in any of the cells (ERα
photographs and graphs for Hs578T and MDA-MB-468 were not shown for ERα
since none was present when tested).
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Table 4.1 ICC Results for Normoxia versus InQ hypoxia versus gCVSL
MCF-7

Hs578T
nuclear
ERα

nuclear

present heavy

ERα

normoxia

HIF-1α
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nuclear
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↓↓↓
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↑

HIF-1α

↑

↑
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cytoplasm
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↓↓↓

absent

present

present

CA9
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HIF-1α
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HIF-1α
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nuclear

cytoplasm
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↑

↑
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↑

↑
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Figure 4.20 Graphs comparing the %CA9 and %HIF-1α for different cell lines in: A) InQ
hypoxia and B) gCVSL.
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Figure 4.21 Comparison of cell lines in normoxia and hypoxia: A) %CA9, B) %ERα.
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Figure 4.22 Comparison of cell lines in normoxia and hypoxia for HIF-1α.
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4.3.5

Mitochondria Morphology in gCVSL
To analyze the morphology of mitochondria in cells grown in gCVSL, live

cell mitochondria experiments were done on mouse 3T3 embryonic fibroblasts,
MCF-7, and Hs578T cells using Mitotracker CMXRos red. Mitochondrial shapes
and location were determined as described in 4.2.7.
To test to see if mitochondrial changes can indicate hypoxia several
gCVSL experiments were set up. For one experiment the MCF-7 cells were done
with Mitotracker red variation one. At 3 hours, live adherent MCF-7
mitochondria were perinuclear and swollen with some donut shapes in cells at
the center of the gCVSL (Figure 4.23 A) but along the edge the mitochondria
were located throughout the cytoplasm (photograph not shown). At 24 hours,
MCF-7 mitochondria were perinuclear and swollen in cells at the center, mid,
and edge regions of the gCVSL. At 48 hours, the results were basically the same
as at 24 hours. At 96 hours, mitochondria were perinuclear and swollen but
fewer mitochondria were visible (Figure 4.23 B). In cells at 3 hours of hypoxia
there were an average of 32 (range 29-37) mitochondria in the cells photographed
but in the 96 hour cells there were only an average of 15 (range 4-20)
mitochondria in the cells photographed.
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Figure 4.23 Mitochondria (red): A and B) live MCF-7 cells in gCVSL center; C) timeline
for the photographs A and B; D) live MCF-7 cells grown in normoxia (photographs are
630x magnification)

148

The same gCVSL experiments were done on Hs578T cells to see if there
was a difference in the mitochondria in these cells. At 3 hours, live adherent
Hs578T mitochondria were short tubular structures in cells at the center (Figure
4.24 A), mid, and edge regions of the gCVSL. At 24 hours Hs578T mitochondria
were in swollen clusters in cells in the center region of the gCVSL but still short
tubular structures in cells in the mid region. Along the edge region of the gCVSL
the mitochondria were tiny and diffuse in the cells. At 48 hours Hs578T
mitochondria were still clustered but they were larger and there were fewer of
them in the center and mid regions of the gCVSL. Along the edge there were no
visible mitochondria in the cells. At 96 hours Hs578T mitochondria were in
clusters in the center but the mitochondria in cells in the mid and edge regions
were starting to form short tubular structures again and now there were more
mitochondria visible (Figure 4.24 B).
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Figure 4.24 Mitochondria (red): A and B) live Hs578T cells in gCVSL center; C)
timeline for the photographs A and B; D) live Hs578T cells grown in normoxia
(photographs are 630x magnification)
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Figure 4.25 shows Hs578T cells that were grown in gCVSL (mid region)
using mitotracker red variation two. Cells were then fixed so confocal
microscopy could be done. Circular (donut) mitochondria can be seen which is
indicative of hypoxic and/or low glucose conditions but there was still excess red
in the cytoplasm.

Figure 4.25 Hs578T cells were grown in gCVSL (mid region). Cells were fixed so
confocal microscopy could be done. (630x magnification)
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The gCVSL experiments were done on MDA-MB-468 cells to see if there
was a difference in the mitochondria in these cells (Figure 4.26). The center
region had mitochondria that were swollen and clustered while the mid region
had small individual mitochondria scattered throughout the cytoplasm.

A

B

Figure 4.26 Mitochondria (red): MDA-MB-468 grown in gCVSL in A) center region, B)
mid region (630x magnification)

To test to see if mitotracker red can diffuse to cells in the gCVSL, MCF-7
and Hs578T cells were grown using mitotracker red variation two and the
mitotracker red was allowed to diffuse for 70 and 90 minutes respectively. Live
cell microscopy was done on the cells after incubation (without rinsing the
mitotracker off of the cells between the coverslip). Neither seventy nor ninety
minutes was enough time for the mitotracker red (MW 531.52 g/mole) to diffuse
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completely to the mitochondria in the center region but it did start to diffuse to
the cells (Figure 4.27).
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Figure 4.27 Mitotracker red (red): A cluster of live MCF-7 cells in the mid to center
region of the gCVSL (630x magnification)

Comparison of mitochondria in cells
Figure 4.28 shows comparison of MCF-7 and Hs578T cells in normoxia,
InQ hypoxia, and gCVSL. Mitochondria in MCF-7 are small and circular “balls”
located throughout the cytoplasm in normoxia and InQ hypoxia. The circular
mitochondria are perinuclear and fewer in number in gCVSL hypoxia.
Mitochondria in Hs578T are short and tubular in normoxia but they are circular
in InQ hypoxia. In 3 hour gCVSL the mitochondria are still short and tubular like
those found in normoxia but with time they become small individual
mitochondria with some forming clusters throughout the cytoplasm.
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Figure 4.28 Comparison of mitochondria (red) in MCF-7 and Hs578T cells in normoxia,
InQ hypoxia, and gCVSL.

4.3.6

Drug Studies in gCVSL
In gCVSL cytotoxicity experiments, samples were observed

microscopically to see if MTT crystals would form in the center, mid, and/or edge
regions. Crystals indicate live cells.

MCF-7 cells
In MCF-7 cells the media “control” after 6 days of growth there were tiny
crystals formed in the center region of the gCVSL. Crystals became more
numerous and larger toward the edge region of the gCVSL (Figure 4.29). MCF-7
cells with DMSO using MTT variation two formed crystals in the edge region,
smaller and fewer crystals formed in the mid region, but no crystals were formed
in the center region (Figure 4.30). Tingenone, which should kill the cells, did kill
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MCF-7 cells in the edge regions so very few crystals were formed. Tingenone did
form crystals in the mid and center regions indicating live cells (Figure 4.31). All
photographs were taken approximately 24 hours after MTT was added.
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Figure 4.29 MTT cytotoxicity assay: MCF-7 cells after growth in gCVSL without a drug
compound (media control): A) center region, B) mid region, C) edge region (all
photographs are 100x magnification), D) timeline for assay
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Figure 4.30 MTT cytotoxicity assay: MCF-7 cells after growth in gCVSL with DMSO
added in A) center region, B) mid region, C) edge region. (all photographs are 100x
magnification), D)timeline for assay
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Figure 4.31 MTT cytotoxicity assay: MCF-7 cells after growth in gCVSL with 1%
tingenone added in A) center region, B) mid region, C) edge region (all photographs are
100x magnification), D) timeline for assay
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MCF-7 cells with Caffeine added as a drug formed crystals in center, mid,
and edge regions of the gCVSL (Figure 4.32).

A
day 0

cells
plated

B
day 4

caffeine
added

day 6

MTT
added

C

day 7

photo
taken

D
Figure 4.32 MTT cytotoxicity assay: MCF-7 cells after growth in gCVSL with caffeine
added in A) center region, B) mid region, C) edge region (all photographs are 100x
magnification), D) timeline for assay
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To check out diffusion and drug concentration issues, experiments were
set up with MCF-7 cells with drug plated at the same time (MTT variation one) in
gCVSL. In the cells grown with Sanguinarine, a compound that kills MCF-7 cells
in normoxia, tiny crystals were formed in the center region with many crystals
(live cells) toward the edge region (Figure 4.33).
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Figure 4.33 MTT cytotoxicity assay: MCF-7 cells were plated along with Sanguinarine in
A) center region, and B) edge region (all photographs are 100x magnification), C)
timeline for assay
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Hs578T cells
Hs578T cells grown with media for 6 days grew crystals and were alive in
the center, mid, and edge regions of the gCVSL (Figure 4.34). Hs567T cells with
DMSO using MTT variation two had less crystals in the center region but the mid
and edge regions still had crystals (Figure 4.35). Hs578T cells were dead (no
crystals) along the edge region when the tingenone drug was present (Figure
4.36). In the mid region the cells with tingenone had crystals present indicating
live cells. In the center region had very few crystals in the tingenone sample. All
photographs were taken approximately 24 hours after MTT was added.
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Figure 4.34 MTT cytotoxicity assay: Hs578T cells after growth in gCVSL without drug
compound (media control): A) center region, B) mid region, C) edge region (all
photographs are 100x magnification), D) timeline for assay
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Figure 4.35 MTT cytotoxicity assay: Hs578T cells after growth with DMSO in A) center
region, B) mid region, C) edge region (all photographs are 100x magnification), D)
timeline for assay
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Figure 4.36 MTT cytotoxicity assay: Hs578T cells after growth with 1% tingenone in A)
center region, B) mid region, C) edge region (all photographs are 100x magnification), D)
timeline for assay
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Hs578T cells were also grown with caffeine added as a drug using MTT
variation two. Photographs were taken approximately 24 hours after MTT was
added (Figure 4.37). Cells in the edge and mid regions had crystals indicating
live cells. Cells in the center had fewer crystals indicating more dead cells in this
region.
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Figure 4.37 MTT cytotoxicity assay: Hs578T cells after growth with caffeine in A) center
region, B) mid region, C) edge region (all photographs are 100x magnification), D)
timeline for assay
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Hs578T were grown with 1% doxorubicin using MTT variation two in
gCVSL (Figure 4.38). There were no crystals in the edge sample indicating dead
cells with doxorubicin. Crystals were present in the mid region indicating that
the cells in this region are alive. Some crystals were also formed in the center
region.
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Figure 4.38 MTT cytotoxicity assay: Hs578T cells after growth with 1% doxorubicin in
A) center region, B) mid region, C) edge region (all photographs are 100x magnification),
D) timeline for assay
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MDA-MB-468 cells
The MDA-MB-468 cells were grown for 12 day with 1% doxorubicin
using MTT variation two. At the edge of the gCVSL crystals are present
indicating that the cells are alive (Figure 4.39). The cells in the mid region had
tiny crystals as well as dark areas present.
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Figure 4.39 MTT cytotoxicity assay: MDA-MB-468 cells after growth with 1%
doxorubicin in A) mid region, and B) edge region (all photographs are 100x
magnification), C) timeline for assay
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Mouse 3T3
Mouse 3T3 fibroblasts were cultured for 4 days in media then MTT
solution was added. Crystals formed in the center, mid, and edge regions of the
gCVSL indicating that the cells were alive (Figure 4.40). When the cells were
cultured with DMSO using MTT variation two crystals formed in the center,
mid, and edge regions of the gCVSL indicating that the cells were alive (Figure
4.41). The same was done with tingenone in place of DMSO and no crystals
formed in the edge region indicating dead cells but crystals did form in the mid
and edge regions of the gCVSL (Figure 4.42).
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Figure 4.40 MTT cytotoxicity assay: 3T3 cells after growth in A) center, B) mid, C) edge
(all photographs are 100x magnification), D) timeline for assay
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Figure 4.41 MTT cytotoxicity assay: 3T3 cells after growth with DMSO in A) center, B)
mid, C) edge (all photographs are 100x magnification), D) timeline for assay

A

C

B

day 0

day 2

cells
plated

Tingenone
added

day 4

MTT
added

day 6

photo
taken

D
Figure 4.42 MTT cytotoxicity assay: 3T3 cells after growth with 1% tingenone in A)
center, B) mid, C) edge (all photographs are 100x magnification), D) timeline for assay
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4.4

gCVSL Discussion
gCVSL was developed and tested as a new method to culture cells under

hypoxia. Our research showed that MCF-7, Hs578T, MDA-MB-468, CAMA-1,
and mouse 3T3 cells grew and divided in RPMI 1640 feeding media, pH 7.3, in
gCVSL. Trypan blue, which is excluded in cells with an intact membrane, was
not found in the majority of the cells in gCVSL indicating live cells.
Endogenous proteins, ERα, CA9, and HIF-1α, were used to determine if
hypoxia was achieved in the gCVSL. These results were compared to the results
from InQ hypoxia. For ERα our research showed that for MCF-7 cells there was a
substantial decrease in the ERα protein level under hypoxia in gCVSL which did
compare to InQ hypoxia results. In gCVSL at 6 hours of cell growth there was
still some ERα protein present but it was no longer present at 24 hours. This
agrees with hypoxia research done by Stoner et al., in 2002 using ZR-75 breast
cancer cells (Stoner et al. 2002). Also in gCVSL the ERα protein reappeared when
the coverslip was removed to allow for reoxygenation to occur. For CA9 and
HIF-1α our research showed that for MCF-7 in gCVSL there was the appearance
of HIF-1α in the cytoplasm and the appearance of CA9 in the nucleus of hypoxic
cells as well as the increase in both CA9 and HIF-1α throughout most cells. For
Hs578T cells both CA9 and HIF-1α increased in the nucleus and cytoplasm of
these cells. For MDA-MB-468 cells both CA9 and HIF-1α appeared in the
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cytoplasm under hypoxia and both CA9 and HIF-1α increased in the nucleus of
these cells. It has been found that nuclear CA9 is enriched in hypoxic cells
(Buanne et al. 2013). Buanne et al, in 2003 were the first to provide evidence that
CA9 interacts with proteins involved in nuclear/cytoplasmic transport, gene
transcription, and protein stability (Buanne et al. 2013). Nuclear CA9 in our cells
as well as an increase in HIF-1α indicates hypoxia. The gCVSL method did
provide regions of hypoxia for cells.
Mitotracker red was used to monitor mitochondria for location and
morphological changes. Changes in mitochondrial morphology can occur under
many conditions. During hypoxia mitochondrial fusion may be altered and it
might contribute to the change in mitochondrial structure (Liu and Hajnoczky
2011). Mitochondrial fusion leads to enlarged mitochondria in hypoxic cells and
cells with enlarged mitochondria are protected from apoptotic stimuli (Chiche et
al. 2010). Swelling of mitochondria can occur during hypoxia in media without
glucose with severe ATP depletion (Liu and Hajnoczky 2011). Donut formation
can occur in media with glucose in hypoxia but more donut formation occurs in
media without glucose in hypoxia. For donut formation there is partial
mitochondrial detachment from the microtubules allowing for mitochondrial
bending and autofusion or inter-fusion of mitochondria, these autofusion and
inter-fusion activities can occur even though there is an overall decrease in
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mitochondrial fusion activities in hypoxia. Our research showed that
mitochondria in MCF-7 cells were perinuclear and swollen within 24 hours in all
regions of the gCVSL, which indicates hypoxia in all regions. Hs578T cells had
short individual or swollen mitochondria in the center regions within 24 hours
indicating hypoxia. The mid region was showing signs of hypoxia at 24 hours
but it was more pronounced at 48 hours. Mitotracker red allowed to sit in the
cells for longer periods of time and then observed live gave better results than
cells that had mitotracker red added for a short period of time then fixed. Short
periods of time may not have allowed all the mitotracker red to enter the
mitochondria or it may not have been removed during the rinse steps so the
fixed cells were not as “clear” to see mitochondria morphology in. Mitochondrial
morphology can be used along with hypoxia markers to monitor hypoxia in cell
cultures.
A modified MTT assay was used to study the effect of drug compounds
on breast cancer cells in gCVSL experiments. MTT crystals could form in all
regions of the gCVSL indicating that the MTT compound could diffuse to the
cells and that the cells were alive.
Assumptions and Limitations for gCVSL
Drug compounds should diffuse to the center regions of the gCVSL. The
diffusion of drug compounds to the center regions of the gCVSL will depend on
168

the density of cells present as well as the viscosity of the drug solution. Was
there a problem with diffusion of compounds to the cells in the center of the
gCVSL since drugs such as tingenone, doxorubicin, and sanguinarine did not kill
all the cells in gCVSL? For cytotoxicity assays, formazan crystals could form in
the center of the gCVSL so the MTT solution which is 414 g/mole can diffuse to
the center. Other compounds that did diffuse into and out of the center region of
the gCVSL included: 1) methylene blue with a molecular weight of 319.85
g/mole, which diffused out (no cells were present), 2) mitotracker red CMXRos
molecular weight of 531.52 g/mole, which did start to diffuse to MCF-7 cells in
the center region of the gCVSL within 70 minutes in Figure 4.27, and 3)trypan
blue with a molecular weight of 872.88 g/mole, which diffused to cells in 48
hours and, once in the cells, it did not diffuse back out, as in example Figures
4.7D and 4.8D. Compounds that should be able to diffuse to the center region of
the gCVSL based on the diffusion of the higher molecular weight compound,
trypan blue, are: 1) DMSO molecular weight of 78.13 g/mole, 2) tingenone
molecular weight of 420.58 g/mole, 3) caffeine molecular weight of 194.19 g/mole,
4) doxorubicin molecular weight 543.52 g/mole, and 5) sanguinarine molecular
weight 332.09 g/mole. Doxorubicin, which is a common cancer drug, killed the
Hs578T cells along the edge regions but did not kill the cells in the mid (hypoxic)
region. Of course the concentration of drug that had diffused to the center within
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24 – 48 hours may not have been sufficient to kill the cells at that point in time.
That may be true in drug diffusion to tumor centers in clinical situations as well.
It is assumed that the MCF-7 cells, which round in the center region of
gCVSL, are experiencing pH issues causing them to round. The MCF-7 cells
grown in InQ hypoxia did not round, so hypoxia was not the cause of cell
rounding. In InQ hypoxia the cells had a large amount of media present
providing them with glucose and pH buffering capacity. This is not true in
gCVSL with limited media present. It is also possible that the lack of poly-lysine
(or other coating material) on the coverslip is playing a role in these cells
rounding, but not other cell lines. The MCF-7 cells may be losing some of their
adherence proteins in the center region of the gCVSL but not the mid and edge
region.
It is assumed that the modified MTT assay is functioning properly in the
gCVSL experiments. The MTT assay in the InQ had reduction of MTT to a purple
solution even in tingenone. Was the reduction due to cells not being killed by
tingenone in InQ hypoxia and gCVSL hypoxia or was there a problem with the
use of the MTT assay in hypoxic conditions?
Advantages of gCVSL
One advantage to the gCVSL compared to the InQ was the ability to work
with live cells in the gCVSL, and the cells will stay hypoxic as long as the
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coverslips remain together. For example cells containing mitotracker red could
be observed live in the gCVSL for the presence or absence of fluorescence while
still remaining hypoxic over a period of days. Another advantage is that the
gCVSL is inexpensive and user friendly. This gCVSL method will now allow
hypoxia experiments to be done in any laboratory.
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CHAPTER 5

DISCUSSION AND CONCLUSIONS

Millions of dollars are spent on target validation and drug optimization
with most therapies failing to make it through clinical trials (Wilding and
Bodmer 2014). A large percentage of chemotherapeutic anticancer drugs are
compounds that interact with DNA directly or prevent the proper relaxation of
DNA through the inhibition of topoisomerases (Palchaudhuri and Hergenrother
2007). Many forms of chemotherapy target the process of cell division with the
rationale being that cancer cells are more likely to be replicating than normal
cells. One common anticancer drug, tamoxifen, is used to treat breast cancer
patients. Seventy percent of all breast cancers overexpress ERα and ERα is the
most important predictor of tamoxifen response (Kronblad et al. 2005). It has
been found that breast cancers that initially respond to tamoxifen treatment
frequently develop resistance (Kronblad et al. 2005). Hypoxia has been shown to
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downregulate ERα in several breast cancer cell lines and consequently the
responsiveness to tamoxifen (Rundqvist and Johnson 2013). Regions of hypoxia
have been found in breast tumors of all stages (Rundqvist and Johnson 2013). In
ductal carcinoma in situ (DCIS) patients, hypoxia and a high degree of necrosis is
associated with a shorter time to recurrence (Rundqvist and Johnson 2013). In
triple negative breast cancer (TNBC), which accounts for a smaller percentage of
breast cancers but a higher percentage of deaths, hypoxia is a prevalent in and
contributes to progression in these TNBC cells (Hunter et al. 2014).
Hypoxia can be found in many human malignancies (Vaupel,
Kallinowski, and Okunieff 1989; Thews et al. 2004; Wouters et al. 2002). Sixty
percent of advanced solid tumors exhibit 1% oxygen or less compared to 2 - 9%
oxygen in adjacent tissue (Favaro et al. 2011). Solid tumors consists of
abnormally formed, poorly functional blood vessels that are incapable of
delivering sufficient oxygen and nutrients to the tumor (Bennewith and Dedhar
2011). While reduced oxygen tensions can be lethal for some cells, many tumor
cells adapt and are able to survive under hypoxic conditions (Bennewith and
Dedhar 2011; Dang 2012). Hypoxic tumor cells promote tumor progression and
metastasis through a variety of direct and indirect mechanisms (Rundqvist and
Johnson 2013; Bennewith and Dedhar 2011). It is well-established that hypoxic
tumor cells are resistant to radiation therapy, some forms of chemotherapy, and
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photodynamic therapy (Bennewith and Dedhar 2011; Vaupel, Thews, and
Hoeckel 2001; Brown 1999).
According to Brown in 1999, there are a number of well-established
conditions that will cause a gradient of reduced cell killing by anticancer agents.
These conditions, which are a function of distance from the blood vessels and
capillaries, include: 1) decreasing oxygen levels which can contribute to drug
resistance through the induction of various hypoxic stress proteins; 2) a pH
gradient: intracellular pH of the cell is highly regulated but the extracellular pH,
which is likely to be lower in the hypoxic areas of the tumor, can affect response
to chemotherapy; and 3) a concentration gradient: anticancer drugs
concentrations will be higher closer to blood vessels and lower near the tumor
(Brown 1999). There are few methods to do drugs studies under conditions like
those seen in tumors.
The gCVSL was developed to provide a new model to use for hypoxia cell
culture. In this method all of Brown’s conditions (oxygen gradient including
regions of hypoxia, pH gradient, and concentration gradient) were tested and
were found to be met.
1) Decreasing oxygen levels to hypoxia
MCF-7, Hs578T, MDA-MB-468, CAMA-1, and 3T3, which grow in normal
cell culture conditions (normoxia), did grow in InQ hypoxia and in gCVSL. The
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InQ instrument (which is no longer available) did provide conditions of hypoxia
when the appropriate gas mixtures were used. InQ hypoxic conditions were
proven using the Ocean Optics dissolved oxygen probe. This probe cannot be
used to test for hypoxia in the gCVSL method so hypoxia protein markers, ERα,
CA9, and HIF-1α, were tested in InQ hypoxia and the results were compared to
the results obtained in the gCVSL. ERα is present in the nucleus of MCF-7 cells
when cultured in normoxia but ERα should decrease in these cells under
hypoxia. Oxygen can diffuse to the center regions of the gCVSL if there are few
cells present and for a few hours after plating. The MCF-7 cells had nuclear ERα
present at 6 hours but as the cells proliferated and used up the oxygen that was
originally present the nuclear ERα eventually decreased. ERα did decrease in
MCF-7 cells in both the InQ and gCVSL experiments indicating hypoxia. HIF-1α
and CA9 should be increased in MCF-7, Hs578T, and MDA-MB-468 if the cells
are under hypoxia. CA9 and HIF-1α increased in MCF-7, Hs578T cells, and
MDA-MB-468 in InQ hypoxia and in all areas in the gCVSL experiment.
The addition of cobalt chloride to cell cultures did not compare to InQ
hypoxia methods. MCF-7 cells did grow in the presence of cobalt chloride, but
the protein marker, ERα, was present in the nucleus of these cells, which was the
same result as for cells grown in normoxia. This protein marker indicates that
hypoxia was not achieved for these cells. HIF-1α and CA9 should both increase
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but in the MCF-7 cells the CA9 was present in the cytoplasm of a few cells but
not all cells. This was an indicator for non-hypoxia. HIF-1α was present in the
nucleus of the normoxic cells and there was an increase of HIF-1α in hypoxic
cells so this one protein marker did indicate hypoxia. The ICC results for MCF-7
cells supplemented with cobalt chloride did not compare to the InQ hypoxia but
the ICC results for the gCVSL did compare to the InQ hypoxia results. The
gCVSL has a continuum of regions from decreasing oxygen levels all the way to
hypoxia.
2) Decreased diffusion of metabolic wastes allows for increased pH in cell
cultures
MCF-7 and Hs578T cells grow and divide in RPMI 1640 feeding media pH
7.3 under normoxia conditions. They can grow in the range of pH 8.69 to 6.66
and retain their usual cell morphology. Once the pH level drops to 5.98 some of
the MCF-7 cells start to detach from the cell culture container; but even then they
can survive down to pH 5.41. At pH 5.03 and below the MCF-7 cells will round
and detach. In gCVSL the Hs578T grow throughout but the MCF-7 cells will
eventually start to detach in the center region of the gCVSL. It is thought that this
is due to the decrease in pH in this region.
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3) Diffusion of drug compounds
For the gCVSL drug studies the diffusion of drug compounds to the center
and mid regions and the determination the final drug concentration needed to
kill these cells will be more like that of a tumor with limited blood supply than to
that in traditional 96 well MTT drug experiments. In general, the compounds
used in this research did diffuse to the center and mid regions of the gCVSL so
this method can be used.
Future Work Using the gCVSL
The gCVSL can be used to screen current cancer drug compounds, to
screen current known prodrugs, and to screen natural products for their ability
to kill cancer cell lines under hypoxia. Once potential compounds are found, the
gCVSL can be used for experiments to determine the mechanism of action of
these compounds.
Research using other types of cells besides solid tumor cells can also
benefit from hypoxic conditions. Low oxygen levels maintain the
undifferentiated states of embryonic, hematopoietic, mesenchymal, and neural
stem cell phenotypes (Mohyeldin, Garzon-Muvdi, and Quinones-Hinojosa 2010).
Cancer stem cells can also be found in hypoxic areas. Cancer stem cells, which
can be found in leukemia, breast, brain, melanoma, colon, and pancreatic
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cancers, strongly correlate with tumor recurrence and treatment failure
(Mohyeldin, Garzon-Muvdi, and Quinones-Hinojosa 2010).
Thermo Fisher Scientific now has a new fluorescent compound for
determining hypoxia in cells. This compound, Image-iT Hypoxia Reagent could
be used to determine the time it takes to achieve hypoxia in the gCVSL for MCF7 cells, Hs578T cells, MDA-MB-468 cells, mouse 3T3 cells, as well as any cells that
can be cultured in gCVSL.
The coverslips used in the gCVSL method can be changed to see what the
effect is. Larger coverslips, round coverslips, or rectangular coverslips can be
used to see if there is a difference in flow of substances to and from the cells
between the coverslips compared to square 22mm x 22 mm coverslip results.
Conclusion
In conclusion, hypoxic regions are present in many tumors and these
regions present a challenge to chemotherapy. The response to chemotherapy is
dependent on the cell’s protein levels, genetic make up, metabolism, and other
cellular responses which can vary between different cells in the same tumor.
Many drugs fail because they are effective on only a subset of cells. One way to
overcome this problem is to attack different key pathways of the cancer process
at the same time with combination therapies. If combinations of drugs are to be
tested the number of mice that would be required for any kind of in vivo
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approach would be impractical. In the new gCVSL method, regions of hypoxia
can be achieved and this ability to change the in vitro cell culture environment
enhances the value of cell lines for drug discovery and development.
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APPENDIX A INQ BIOSYSTEM

Some of the product specifications for the InQ beta unit are found here
along with the oxygen measurements charts done by an InQ technician.
Measurements were taken using an Ocean Optics dissolved oxygen probe in an
empty InQ cassette to measure cycling between 1% oxygen (hypoxia) and
atmospheric oxygen (normoxia).
The results are:
Without solution or cells the cycling from 1% oxygen to 19% oxygen takes
approximately 16 minutes and then from 19% oxygen back to 1% oxygen it also
takes approximately 16 minutes. Oxygen measurements were also taken using a
dissolved oxygen probe in an empty InQ cassette starting at 1% oxygen, hypoxia,
and then media was added through the septa at the front of the cassette. The
probe measured approximately 13.8% oxygen when it was inserted into the
media. The media dissolved oxygen levels immediately started to decline and
reached 2% oxygen within 14 minutes and then reached approximately 1.5%
oxygen within 17 minutes. The oxygen measurements were done without cells
in the InQ cassettes. The InQ did provide a hypoxic environment for cells.
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Part of the InQ Biosystem Specification Sheets
INSTRUMENT 15-0001
The InQbio™ PLUS Automated Cell Research System provides the infrastructure
and controls for cell growth including gas and temperature control as well as the
precise delivery and removal of media. Cell culture parameter data and images
are collected and conveyed using a built-in microscope, computer and InQwell™
Software. The control computer sequences the experiment according to a userdefined protocol. Data and images are available to the local network and via the
Internet.
BENCHTOP INSTRUMENT: 27.5”H X 21”W X 20”D
WEIGHT: ~180 LBS (81.64 KG)
POWER: 110-220VAC, 50-60 HZ, 550 Watts
NETWORK CONNECTIONS: RJ45 100-1000 MB Ethernet. 2 USB ports.
PHASE CONTRAST INVERTED MICROSCOPE: 4X or 10X Objective with
Digital Magnification
DIGITAL CAMERA
TEMPERATURE RANGE: 27- 40 OC Accuracy +/- 0.1 OC
GASES UP TO 4 TYPES (AIR, O2, N2, CO2, CO, CUSTOM BLEND): Accuracy
+/- 0.2%
MEDIA DELIVERY: 0.2 - 2 ml / min
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_______________________________________________________________________
CELL GROWTH CASSETTE 1501-001
The sterile growth cassette houses two independently functioning cell growth
chambers. A system of valves and micro-channels directs gas and media flow to
the cells. The cartridge is composed of cell culture compatible, optically clear
polystyrene. Cells may be harvested after trypsin dissociation.
CARTRIDGE DIMENSIONS: 0.5”H x 5.6”W x 3.75”D
GROWTH CHAMBER VOLUME: 12 ml with Surface Area of 12.63 cm2
SURFACES: Culture Grade Polystyrene or Removable Poly-D-Lysine Coated
Glass or Custom Coatings Available Upon Request
CELL TYPES: Adherent Cells
_______________________________________________________________________
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Chart done by InQ Biosystem
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Chart done by InQ Biosystem
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APPENDIX B NATURAL PRODUCT STUDIES

Natural products have been used by many cultures for medicinal
purposes. Plant extracts and essential oils from plants were used as compounds
in cytotoxicity assays. These results supplement the results listed in Tables 2.1,
2.2, and 2.3 in the text.
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Costa Rica 2008 Natural products tested against cell lines
Normoxia

CR08
CR08
CR08
CR08
CR08
CR08
CR08
CR08
CR08
CR08
CR08
CR08
CR08
CR08
CR08
CR08
CR08
CR08
CR08
CR08
CR08
CR08
CR08
CR08
CR08
CR08
CR08
CR08

Drug #

Drug initials

1
2
3
4*
5
6*
7*

INONBA
VETURA
RUPHBA
EUMOBA
BUNSBM
SAMOLA
SAMOLA
CEMEBA
SPPUSR
COERBA
CRMOBA
CEMEBA
EUMOBA
TAMEBC
LOOLA
SECOLA
SASPBM
CRDABA
KOPIBA
BUNSBC
SAPILA
ALPIBA
VETUBA
PELOB
TOPELA
TUOCL
VIVELA
SASPBD

8* yellow
9
10
11
12*green
13*
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

"normal" cell line
3T3 (mouse)
%kill
want alive
22.94
105.44
46.99
33.96
7.31
-7.37
0.18
-7.07
32.09
0.11
100.56
30.72
104.89
24.85
28.09
16.91
7.22
31.82
103.4
-0.5
39.4
106.93
29.12
-22.43
39.9
92.29
107.02
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human breast cell lines
MCF-7
Hs578T
%kill
%kill
want dead
want dead
5.59
-8.08
108.99
108.99
8.65
0
22.11
12.68
16.88
0
44.06
0
see #6
0
14.06
11.64
10.15
0
6.91
6.6
36.87
32.06
70.12
111.01
see #4
32.42
46.88
107.27
6.87
-27.89
17.94
0
7.77
4.1
22.87
0
30.54
0
49.95
112.8
11.5
46.58
29.95
23.12
107.14
107.45
5.99
-5.08
51.15
-3.12
12.41
-20.35
14.5
-14.72
106.54
104.37

Costa Rica 2008 Natural Product Essential Oils tested against cell lines
Normoxia

CR08 EO
CR08 EO
CR08 EO
CR08 EO
CR08 EO
CR08 EO
CR08 EO
CR08 EO
CR08 EO
CR08 EO
CR08 EO
CR08 EO
CR08 EO
CR08 EO
CR08 EO
CR08 EO
CR08 EO
CR08 EO
CR08 EO
CR08 EO
CR08 EO
CR08 EO
CR08 EO
CR08 EO
CR08 EO
CR08 EO
CR08 EO
CR08 EO
CR08 EO
CR08 EO
CR08 EO
CR08 EO
CR08 EO
CR08 EO
CR08 EO
CR08 EO
CR08 EO
CR08 EO
CR08 EO

"normal" cell line
Drug #

Drug initials

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39

ORNUEO
LITREO
EUMOEO#1
EUMOEO(f)
LAVEEO#2
POEMEO
VETUEO
HYPEEO
LACAEO
BEFOEO#2
BRCOLEO
CAEDEO#1
EUMOEO#2
RHKUEO
LAVEEO#1
LTUPFA3
NEANEO
CLLEEO
BEFOEO#1
LTUPFA1
GUCOEO
CYCOEO
LTUPFB3
PESCEO
LTUPFA2
MOGUEO#3
MOGUEO#2
LTUPFB1
MOGUEO#1
LTUPFB2
DEMAEO
GUDIEO
LAHIEO
DEBIEO
ZAPBEO
DELLEO
SCROEO
BRRFEO
BRCOBEO
LTUPA4
LTUPA5
LTUPB4
LTUPB5

human breast cell lines

3T3 (mouse)
%kill

MCF-7
%kill

Hs578T
%kill

want alive
30.46
-2.3
-4.17
-1.05
25.34
107.48
46.34
-2.59
-11.69
-0.14
-3.92
1.23
12.74
-2.79
-2.75
76.04
-6.37
107.91
-9.88
91.16
2.39
104.33
7.58
-1.94
7.24
10.04
102.03
10.83
46.26
80.24
50.74
103.63
15.55
42.7
-1.5
29.34
5.87

want dead
22.28
19.33

want dead
40.83
8.82
18.79
30.47
-10.09
42.13
32.43
12.59
0.1
5.8
43.72
-1.41
-13.07
-9.14
-24.84
23.25
-21.21
5.41
-8.01
13.12
-17.99
17.03
21.78
-15.05
19.63
-28.75
6.51
8.66
-12.31
54.62
8.21
21.05
-8.76
53.54
9.75
27.52
31.31

17.33
53.3
45.09

13.78

52.55

72.89
13.74

3.14

14.58

103.49
104.89

44.65
46.46
68.57
20.11
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Costa Rica 2009 Natural Products tested against cell lines
Normoxia

CR09
CR09
CR09
CR09
CR09
CR09
CR09
CR09
CR09
CR09
CR09
CR09
CR09
CR09
CR09
CR09
CR09
CR09
CR09
CR09
CR09
CR09
CR09
CR09

Drug #

Drug initials

901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924

TALOLC
PIAELA
VETUBA
PAMABM
MAVEVA
VEOEBA
DRALBA
TALOBC
VEOELA
TAMEBC
TRMABA
MAOPBA
VIVELC
ZABRBA
PAMABC
EUELBM
OCSIBA
TALOBM
BRINBC
BRINBM
GUKUBA
TALOLM
CESOPA
BYCRBA

"normal" cell line
3T3 (mouse)
%kill
want alive

81.4
-16.69

100.16
106.01
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human breast cell lines
MCF-7
Hs578T
%kill
%kill
want dead
want dead
20.73
32.75
54.79
33.02
101.41
99.76
24.08
-0.08
24.57
-0.45
90.77
96.94
54.03
16.12
66.78
95.55
102.38
99.72
101.59
99.97
88.1
101.16
67.91
69.34
68.2
99.32
104.09
103.35
104.05
103.12
104.23
102.8
49.11
50.37
46.56
16.58
70.39
60.17
13.37
0.3
103.22
99.59
16.44
20.58
46.61
40.79
72.24
58.58

Miscellaneous Natural Products and cancer drugs tested against cell lines
Normoxia
Drug #

Drug initials

15
21
30
12

lupeol
citral
methoxypsoralen
8-methoxypsoralen
bornyl acetate
β-ocimene

"normal" cell line
3T3 (mouse)
%kill
want alive
52.05
102.63
40.42
86.99
100.97
104.43

ACAR
DRCO

90.08
103.43

CR96
CR96
CR09 EO
CR09 EO
CR09 EO
CR09 EO
CR09 EO
CR09 EO
CR09 EO
CR09 EO
CR09 EO

41
42
43
44
45
46
47
48
49

FLPYLEO
BLPEEO
EUODEO
VEOELEO
CULUEO
CEODBEO
VEOEBEO
BUSIBEO
BUSILEO
1% Doxorubicin
0.001% Doxorubicin
1% Camptothecin
0.01% Camptothecin
0.001% Camptothecin
Vinblastine (0.0599µM)
Paclitaxel (0.25µM)

-18.57
-24.29
26.34
65.18
22.83
38.32
38.68
100.44
55.71
97.31
20.1
66.58
20.57
12.19
43.86
50.81
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human breast cell lines
MCF-7
Hs578T
%kill
%kill
want dead
want dead
65.97
90.98
96.59
1
42
16
34
19
27
101.16
98.47

24.95
-38.94
20.63
38.05
-1.55
-6.12
-9.43
100.29
-10.47
100.95
27.63
77.4
73.15
65.24
51.04
57.76

87.7
32.41
117.07
56.41
27.49
67.83
90.69

Costa Rica 2008 Natural Products (CR08)
Extract Code

Plant Name

INONBA

Inga sp. "one hectary"

VETURA

Verbesina turbacensis

RUPHBA

Ruyschia phylladenia

EUMOBA

Eugenia monteverdensis

BUNSBM

Bursera NOT Simaruba

SAMOLA

Saurauia montana

SPPUSR

Spondias purpuria

COERBA

Cordia eriostigma

CRMOBA

Critonia morifolia

CEMEBA

Cestrum megalophyllum

TAMEBC

Tapirira mexicana

LOOLA

Lonchocarpus oliganthus

SECOLA

Senecio cooperi

SASPBM

Salacia sp. "liama"

CRDABA

Critonia daleoides

KOPIBA

Koanophyllon pittieri

BUNSBC

Bursera NOT Simaruba

SAPILA

Sauria pittieri
190

ALPIBA

Alstoria pittieri

VETUBA

Verbesina turbacensis

PELOB

Perottetia longistylis

TOPELA

Tovaria pendula

TUOCL

Turpinia occidentalis

VIVELA

Viburnum venustum

SASPBD

Salacia sp. "liama"

Costa Rica 2008 Natural Products Essential Oils (CR08 EO)
EO Code

Plant Name

ORNUEO

Oreopanax nubigenus

LITREO

Licaria triandra

EUMOEO #1

Eugenia monteverdensis (leaf EO #1)

EUMOEO(F)

Eugenia monteverdensis (fruit EO)

LAVEEO #2

Lantana velutina (leaf EO #2)

POEMEO

Podachaenium eminens

VETUEO

Verbesina turbacensis (bark EO)

HYPEEO

Hydrangea peruviana

LACAEO

Lantana camara

BEFOEO #2

Besleria formosa (leaf EO #2)
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BRCOLEO

Brunellia costaricensis (leaf EO)

CAEDEO #1

Casimiroa edulis (leaf EO #1)

EUMOEO #2

Eugenia monteverdensis (leaf EO #2)

RHKUEO

Rhodostemonodaphne kunthiana

LAVEEO #1

Lantana velutina (leaf EO #1)

LTUPFA3

L. tulipifera A #3

NEANEO

Neomirandea angularis (leaf EO)

CLLEEO

Clibadium leiocarpum

BEFOEO #1

Besleria formosa (leaf EO #1)

LTUPFA1

L. tulipifera A #1

GUCOEO

Guatteria costaricensis

CYCOEO

Cymbopetalum costaricense

LTUPFB3

L. tulipifera B #3

PESCEO

Persea schiediana

LTUPFA2

L. tulipifera A #2

MOGUEO #3

Montanoa guatemalensis (leaf EO #3)

MOGUEO #2

Montanoa guatemalensis (leaf EO #2)

LTUPFB1

L. tulipifera B #1

MOGUEO #1

Montanoa guatemalensis (leaf EO #1)

LTUPFB2

L. tulipifera B #2
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DEMAEO

Desmopsis macrocarpa

GUDIEO

Guatteria dispyroides

LAHIEO

Lantana hirta

DEBIEO

Desmopsis bibracteata

ZAPBEO

Zanthoxylum sp "Penas Blancas"

DELLEO

Dendropanax sp "large leaf"

SCROEO

Schefflera rodrigueziana

BRRFEO

Brugmansia suaveolens (rose floral EO)

BRCOBEO

Brunellia costaricensis (bark)

Costa Rica 2009 Natural Products (CR09)
Extract Code

Plant Name

TALOLC

Tabernaemontana longipes

PIAELA

Piper aequale

VETUBA

Verbesina turbacensis

PAMABM

Paullinia cf macrocarpa

MAVEVA

Mandevilla veraguasensis

VEOEBA

Verbesina oerstediana

DRALBA

Drypetes alba

TALOBC

Tabernaemontana longipes

VEOELA

Verbesina oerstediana
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TAMEBC

Tapirira mexicana

TRMABA

Trichilia martiana

MAOPBA

Matayba oppositifolia

VIVELC

Viburnum venustum

ZABRBA

Zanthoxylum sp "brillante"

PAMABC

Paullinia cf macrocarpa

EUELBM

Euphorbia elata

OCSIBA

Ocotea sinuata

TALOBM

Tabernaemontana longipes

BRINBC

Bravaisia integerrima

BRINBM

Bravaisia integerrima

GUKUBA

Guarea kunthiana

TALOLM

Tabernaemontana longipes

CESOPA

Centropogon solanifolius

BYCRBA

Byrsonima crassifolia

Costa Rica 1996
Extract Code
ACAR

Plant Name
natural product

DRCO

natural product

194

Costa Rica 2009 Natural Products Essential Oils (CR09 EO)
Extract Code

Plant Name

FLPYLEO

Fleischmannia pycnocephala Leaf

BLPEEO

Blumea perrottetianna

EUODEO

Eupatorium odoratum

VEOELEO

Verbesina oerstediana Leaf

CULUEO

CULUEO (CR09)

CEODBEO

Cedrela odorata Bark

VEOEBEO

Verbesina oerstediana Bark

BUSIBEO

Bursera simaruba Bark (CR09)

BUSILEO

Bursera simaruba Leaf (CR09)
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